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Abstract
In osteoarthritis (OA), synovitis is associated with symptom severity. As synovium secretes
both catabolic and anabolic factors into the joint, the impact of synovitis in OA remains
unclear. We developed a novel co-culture system using tissues from an established rat model
of post-traumatic knee OA (PTOA) to study signaling between synovium and chondrocytes.
We found that synovium from early stage but not later stage PTOA joints caused an overall
protective effect in chondrocytes. We then selectively treated synovial macrophages with
liposomal drugs causing depletion, STAT1 inhibition, or STAT6 inhibition in early PTOA
joints. We found cartilage damage in vivo was not affected, but chondrocyte responses to
treated synovium in vitro indicate that STAT1 inhibition could be protective, while STAT6
inhibition is potentially pro-inflammatory. Thus, we demonstrate that synovial signals affect
chondrocyte physiology in the OA knee joint and that targeting synovial macrophages as a
potential therapeutic strategy warrants further investigation.

Keywords
Animal model of disease, cartilage, chondrocyte, inflammation, liposomal drug delivery,
osteoarthritis, synovial macrophages, synovium, STAT inhibitors, tissue culture.
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Lay Summary
Osteoarthritis is a serious joint disease that causes pain and disability with no direct
treatment. Patients manage symptoms with pain medication and exercise. We still do not
completely understand the mechanisms behind osteoarthritis, but we do know that the disease
involves the cells in cartilage on the ends of bones changing from their normal state to send
out inflammatory signals and enzymes that destroy the tissue around them. The joint lining,
or synovium, which wraps around the joint space, also changes by becoming inflamed. In my
project, we investigated how the synovium signals to cartilage cells and how the condition of
the synovium affects osteoarthritis in the joint.
Our experiments used young adult male rats following ethical guidelines. We surgically
injured the rats’ knees to induce osteoarthritis. We collected cartilage and synovium and
grew them in artificial conditions to isolate the signals exchanged between these tissues.
Because inflamed synovium is correlated with human disease severity, we hypothesized that
growing early osteoarthritic synovium with healthy cartilage cells would cause them to
become inflammatory and destructive. To our surprise, we found a protective effect with
indications of increased production of tissue molecules by cartilage cells. We then grew
synovium from joints at a later stage of osteoarthritis with cartilage cells and found that this
protective effect was completely absent. From this, we concluded that the synovium
undergoes a change over time, which has implications for our understanding of osteoarthritis,
although these findings need to be confirmed in humans.
We then investigated the impact of macrophages in the synovium in osteoarthritis.
Macrophages are a diverse immune cell population with important roles in the joint,
especially signaling. We packaged different drugs into small lipid particles and injected them
into pre-osteoarthritic knees, where only macrophages could consume the drugs. For the
three drugs we tested, we found different patterns of reduced inflammation in the synovium
and mixed effects in cartilage cells grown with the synovium, but no differences in cartilage
damage or pain. Our future work will use knees at a later stage of osteoarthritis, where we
expect to see significant results in osteoarthritis-related outcomes.

ii

Acknowledgments
In no particular order, my appreciation goes to:
Drs. Frank Beier and Cheryle Séguin, and their lab members, particularly Dr. Mike Pest,
Dawn Bryce, Holly Dupuis, and Courtney Brooks, for being always approachable and
forming a community of learning about both scientific theory and practice;
Neighbouring labs in the Schulich community, including the Flynn, Goldberg, Hamilton, and
Di Guglielmo labs, who have offered their equipment, reagents, and expertise;
Dr. Elizabeth Gillies of the Department of Chemistry, and the students in her lab who offered
their help while I was fumbling my way around making liposomes;
Drs. Dean Betts and Rodney DeKoter, my advisory committee members;
Garth Blackler, Dan Klapak and Ryan Beach, all hard-working lab technicians, who have
listened to me stress and ramble on about a great deal of things, both lab-related and not;
Holly Philpott, my labmate and a bright example of a PhD student, who has offered me
perspective;
Drs. Kyle Pitchers and Gaelle Wambiekele, post-doctoral scholars who were there from the
start of the lab and taught me about working and communicating with others;
My supervisor, Dr. Tom Appleton, a gracious human being, a brilliant principal investigator,
and undoubtedly someone who has touched many lives and will reach many more;
Aisa, Abdullah, and Bethia, for their friendship and empathy;
And Benson, my other half and my well of support.

Thank you all.

iii

Table of Contents
Abstract ........................................................................................................................... i
Keywords ........................................................................................................................ i
Lay Summary ................................................................................................................. ii
Acknowledgments ......................................................................................................... iii
Table of Contents .......................................................................................................... iv
List of Tables............................................................................................................... viii
List of Figures ............................................................................................................... ix
List of Appendices ........................................................................................................ xii
List of Abbreviations ................................................................................................... xiii
Chapter 1 .........................................................................................................................1
Introduction ................................................................................................................1
1.1 The Synovial Joint ...............................................................................................2
Articular Cartilage ....................................................................................2
Synovium .................................................................................................3
1.2 Osteoarthritis .......................................................................................................7
Etiology....................................................................................................7
Pathobiology ............................................................................................8
Disease Burden ....................................................................................... 11
Disease-Modifying Treatment for OA .................................................... 11
Animal Models of OA ............................................................................ 12
1.3 Research Question ............................................................................................. 16
Rationale ................................................................................................ 16
Hypothesis.............................................................................................. 16
Objective ................................................................................................ 17
1.4 References ......................................................................................................... 19
iv

Chapter 2 ....................................................................................................................... 24
A novel ex vivo joint co-culture system for investigating synovium-chondrocyte
interactions demonstrates protective effects of synovium in early experimental
osteoarthritis. ............................................................................................................ 24
2.1 Chapter Summary .............................................................................................. 25
2.2 Introduction ....................................................................................................... 26
2.3 Materials and Methods ....................................................................................... 29
Reagents ................................................................................................. 29
Experimental PTOA rat model................................................................ 29
Cell and tissue cultures ........................................................................... 30
Tissue histology and immunohistochemistry........................................... 31
Dimethylmethylene blue (DMMB) assay ................................................ 31
RNA isolation and gene expression analysis ........................................... 33
TGFBR1 inhibition and FOXO1 inhibition assays .................................. 35
Statistics ................................................................................................. 36
2.4 Results ............................................................................................................... 37
P0 articular chondrocytes express baseline inter-individual variation ...... 37
P1 articular chondrocytes maintain a chondrocyte-like phenotype .......... 37
Synovial tissue remains viable in serum-free culture ............................... 41
Early PTOA synovium induces changes in primary articular chondrocyte
physiology .............................................................................................. 41
Later stage PTOA synovium alters Ccl2 expression in primary articular
chondrocytes .......................................................................................... 46
Effects of early PTOA synovium on primary articular chondrocytes is not
fully replicated by conditioned medium transfer ..................................... 50
2.5 Discussion.......................................................................................................... 54
2.6 References ......................................................................................................... 61
Chapter 3 ....................................................................................................................... 68
v

Targeting synovial macrophage activation affects chondrocyte and joint outcomes in
experimental post-traumatic osteoarthritis. ................................................................ 68
3.1 Chapter Summary .............................................................................................. 69
3.2 Introduction ....................................................................................................... 71
3.3 Materials and Methods ....................................................................................... 75
Reagents ................................................................................................. 75
Liposome source and manufacture .......................................................... 75
Experimental PTOA rat model................................................................ 77
Tissue histology and histopathological scoring ....................................... 77
Pain-related animal behavior measurements ........................................... 78
Joint tissue cultures and co-culture system .............................................. 79
Dimethylmethylene blue (DMMB) assay ................................................ 80
RNA isolation and gene expression analysis ........................................... 80
Primary peripheral blood-derived macrophage cultures........................... 81
Statistics ................................................................................................. 83
3.4 Results ............................................................................................................... 84
Targeted drug delivery to synovial macrophages alters features of
synovitis in early PTOA joints ................................................................ 84
Targeted drug delivery to synovial macrophages does not markedly affect
cartilage histopathological scores in early PTOA joints .......................... 84
Targeted drug delivery to synovial macrophages does not induce changes
in pain-related behavior in early PTOA................................................... 84
Targeted drug delivery to synovial macrophages alters articular
chondrocyte physiology .......................................................................... 90
Liposomal drug delivery alters primary peripheral blood-derived
macrophage physiology in vitro .............................................................. 90
3.5 Discussion.......................................................................................................... 97
3.6 References ....................................................................................................... 102
Chapter 4 ..................................................................................................................... 106
vi

Summary and General Discussion ........................................................................... 106
4.1 Establishment of a synovial joint model ex vivo ............................................... 108
4.2 Effects of PTOA synovium condition on chondrocytes .................................... 109
4.3 Future directions .............................................................................................. 111
Appendix A ................................................................................................................. 113
Appendix B ................................................................................................................. 115
Curriculum Vitae ......................................................................................................... 118

vii

List of Tables
Table 2.1. Reference information for Bio-Rad PrimePCR™ PCR primers. ......................... 34
Table 3.1. Reference information for Bio-Rad PrimePCR™ PCR primers. ......................... 82

viii

List of Figures
Figure 1.1. Zonal organization of articular cartilage. ............................................................. 4
Figure 1.2. Organization of synovium. .................................................................................. 5
Figure 1.3. Physiological changes in the osteoarthritic joint. ................................................. 9
Figure 1.4. Articular cartilage damage increases over time in the ACLT-pMMx rat model. 14
Figure 1.5. Schematic of research objectives. ...................................................................... 18
Figure 2.1 Experimental timeline for synovium-chondrocyte co-cultures. ........................... 32
Figure 2.2. sGAG content in conditioned medium from P0 chondrocytes co-cultured with
dissociated primary synoviocytes. ....................................................................................... 38
Figure 2.3. Gene expression in P0 chondrocytes co-cultured at 70% confluency with
dissociated primary synoviocytes. ....................................................................................... 39
Figure 2.4. Gene expression in P0 chondrocytes co-cultured at confluency with dissociated
primary synoviocytes. ......................................................................................................... 40
Figure 2.5. Morphology of P1 chondrocytes during expansion in monolayer culture. .......... 42
Figure 2.6. sGAG content in conditioned medium from P1 chondrocytes in serum-free
conditions without synovial co-culture. ............................................................................... 43
Figure 2.7. Gene expression in P1 chondrocytes in serum-free conditions without synovial
co-culture. .......................................................................................................................... 44
Figure 2.8. Viability of synovial tissue after 48 hours in serum-free co-culture with primary
chondrocytes. ..................................................................................................................... 45
Figure 2.9. sGAG content in conditioned medium from P1 chondrocytes co-cultured with
synovial tissue. ................................................................................................................... 47

ix

Figure 2.10. Gene expression in P1 chondrocytes co-cultured with synovial tissue for 24
hours. ................................................................................................................................. 48
Figure 2.11. Gene expression in P1 chondrocytes co-cultured with synovial tissue for 120
hours. ................................................................................................................................. 49
Figure 2.12. P1 articular chondrocytes incubated with inhibitors of TGFBR1 and FOXO1. 51
Figure 2.13. Prg4 expression levels in P1 articular chondrocytes incubated with conditioned
medium and TGFBR1 inhibitor. ......................................................................................... 52
Figure 3.1. Signalling mediators and cells involved in OA synovitis. .................................. 73
Figure 3.2. Morphology and size distribution of manufactured drug-laden liposomes. ........ 76
Figure 3.3. Low-grade synovitis present in liposome-treated 4W PTOA joints.................... 85
Figure 3.4. CD68+ cells in synovium from clodronate liposome-treated 4W PTOA joints. . 86
Figure 3.5. Histopathological scoring for features of synovitis in liposome-treated 4W PTOA
joints. ................................................................................................................................. 87
Figure 3.6. Low-grade cartilage damage present in liposome-treated 4W PTOA joints. ...... 88
Figure 3.7. Histopathological scoring for cartilage damage in liposome-treated 4W PTOA
joints. ................................................................................................................................. 89
Figure 3.8. Mechanical hyperalgesia in liposome-treated 4W PTOA animals. ..................... 91
Figure 3.9. Tactile allodynia in liposome-treated 4W PTOA animals. ................................. 92
Figure 3.10. sGAG content in conditioned medium from primary articular chondrocytes cocultured with liposome-treated 4W PTOA synovium. ......................................................... 93
Figure 3.11. Gene expression in primary articular chondrocytes co-cultured with liposometreated 4W PTOA synovium. .............................................................................................. 94

x

Figure 3.12. Gene expression in primary peripheral blood-derived macrophages treated with
liposomes and activating factors. ........................................................................................ 96
Figure 4.1. Schematic of research outcomes.......................................................................107

xi

List of Appendices
Appendix A: Animal Use Protocol Approval. ....................................................................113
Appendix B: Animal Research: Reporting In Vivo Experiments (ARRIVE) Guidelines
Checklist. ............................................................................Error! Bookmark not defined.5

xii

List of Abbreviations
Acan

Aggrecan (gene)

ACLT

Anterior cruciate ligament transection

ADAMTS4

A disintegrin and metalloproteinase with thrombospondin motifs 4

ADAMTS5

A disintegrin and metalloproteinase with thrombospondin motifs 5

Adamts5

A disintegrin and metalloproteinase with thrombospondin motifs 5 (gene)

ANOVA

Analysis of variance

Arg1

Arginase 1 (gene)

CCL2

C-C motif chemokine ligand 2

Ccl2

C-C motif chemokine ligand 2 (gene)

CCR2

C-C chemokine receptor type 2

CD68

Cluster of differentiation 68

cDNA

Complementary deoxyribonucleic acid

CI

Confidence interval

COL2A1

Collagen type II, alpha-1 subunit (gene)

Col2a1

Collagen type II, alpha-1 subunit (gene)

Col10a1

Collagen type X, alpha-1 subunit (gene)

COMP

Cartilage oligomeric matric protein (gene)

Cq

Quantification cycle

DAB

3,3'-diaminobenzidine

DAMP

Damage-associated molecular patterns

ddPCR

Droplet digital polymerase chain reaction

DMEM

Dulbecco’s Modified Eagle Medium

DMM

Destabilization of the medial meniscus

DMMB

Dimethylmethylene blue

DMSO

Dimethyl sulfoxide

DNase I

Deoxyribonuclease I

EDTA

Ethylenediaminetetraacetic acid

ERG

Erythroblast transformation-specific-related gene

EVF

Electronic Von Frey

F12

Ham’s F12 medium
xiii

FBS

Fetal bovine serum

FOXO1

Forkhead box protein O1

GDF5

Growth differentiation factor 5 (gene)

H&E

Hematoxylin and eosin

HMGB1

High mobility group box 1

Hprt1

Hypoxanthine-guanine phosphoribosyltransferase (gene)

IFN-γ

Interferon-gamma

IL-1β

Interleukin 1 beta

IL-17

Interleukin 17A

Il17a

Interleukin 17A (gene)

IL-4

Interleukin 4

Il6

Interleukin 6 (gene)

IL-8

Interleukin 8

Mϕ

Macrophage

M-CSF

Macrophage colony-stimulating factor

MCP1

Monocyte chemoattractant protein 1

MIQE

Minimum information for publication of quantitative real-time
polymerase chain reaction experiments

MMP

Matrix metalloproteinase

MMP1

Matrix metalloproteinase 1

MMP13

Matrix metalloproteinase 13

Mmp13

Matrix metalloproteinase 13 (gene)

MMP3

Matrix metalloproteinase 3

Mmp3

Matrix metalloproteinase 3 (gene)

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NFAT

Nuclear factor of activated T cells

Nfatc1

Nuclear factor of activated Tcells, cytoplasmic 1 (gene)

Nfatc2

Nuclear factor of activated Tcells, cytoplasmic 2 (gene)

NFATc4

Nuclear factor of activated Tcells, cytoplasmic 4

OA

Osteoarthritis

OARSI

Osteoarthritis Research Society International

P

Cell passage
xiv

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PGE2

Prostaglandin E2

pMMx

Partial medial meniscectomy

Pop4

Ribonuclease P protein subunit p29 (gene)

Prg4

Proteoglycan 4 (gene)

PTOA

Post-traumatic osteoarthritis

QALY

Quality-adjusted life year

qPCR

Quantitative real-time polymerase chain reaction

RNA

Ribonucleic acid

RPMI 1640

Roswell Park Memorial Institute 1640 medium

Runx2

Runt-related transcription factor 2 (gene)

S100a8

S100 calcium-binding protein A8

S100a8

S100 calcium-binding protein A8 (gene)

S100a9

S100 calcium-binding protein A9

S100a9

S100 calcium-binding protein A9 (gene)

sGAG

Sulfated glycosaminoglycan

SMALGO

Small animal algometer

Sox9

Sex-determining region Y-box transcription factor 9 (gene)

STAT

Signal transducer and activator of transcription

TGF-β

Transforming growth factor beta

Tgfb1

Transforming growth factor beta 1 (gene)

TGFBR1

Transforming growth factor beta receptor I

TIMP

Tissue inhibitor of metalloproteinases

TNF-α

Tumour necrosis factor alpha

Tnf

Tumour necrosis factor alpha (gene)

xv

1

Chapter 1
Introduction
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1.1 The Synovial Joint
The synovial joint is evolution’s solution to the requirements of complex motion in
vertebrates to traverse and manipulate their environment. From the large load-bearing
joints of the lower body to the fine joints of the hand, each point of articulation allows
two or more bones to glide, rotate, or pivot against each other with very little friction.
Whereas fibrous joints tightly sew bones together and cartilaginous joints allow only
semi-flexibility, synovial joints are complex organs comprised of multiple tissue types
working together to lubricate and facilitate movement between bones, transmit
biomechanical forces, and cushion external impact, including bone, cartilage, synovium,
muscle, tendon, and ligament. When disease affects these joints, the resulting pain and
disability reduce quality of life, compound comorbid diseases, and threaten survival.

Articular Cartilage
Articular cartilage is the specialized tissue that makes smooth, painless contact between
bones possible. Cartilage is able to withstand high cyclic loads of mechanical force,
exhibits viscoelasticity, and is resistant to compression and shear forces, with very low
surface friction1,2. These properties are due to its biphasic composition and structure. The
fluid phase of the extracellular matrix, consisting of water and electrolytes, constitutes
65-80% of the wet weight of cartilage. The solid phase includes proteoglycan aggregates,
which make up 3-10% of the wet weight, and the network of collagen, responsible for 1030% of the wet weight3. Proteoglycan aggregates consist of branching chains of
polysaccharides and proteoglycans; each long chain of hyaluronan, the non-sulfated
glycosaminoglycan, links to a high number of proteoglycan molecules, mostly aggrecan,
which itself is linked to many small sulfated glycosaminoglycans, and it is the strong
osmotic force of these sugar chains that maintains the water content of cartilage and
enables it to resist compression4. The collagen network is predominantly type II collagen,
with small amounts of types III, VI, IX, X, XI, XII and XIV as well5. Proteoglycan
aggregates are not directly bound to the collagen network, but instead physically trapped
within.
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Articular cartilage is categorized into the superficial, transitional, and deep zones (Figure
1.1). The superficial zone is higher in water content and has collagen fibres aligned
parallel to the articulating surface with many small, dense chondrocytes. The deep zone
has lower water content due to the increased collagen and proteoglycan content, with
fibres and columns of chondrocytes aligned perpendicular to the articular surface as they
enter the calcified zone. The transitional zone acts as the functional gradient in between
these morphologically distinct zones.
The matrix also differs with proximity to the chondrocytes. A chondrocyte and its
pericellular matrix form a morphologically and mechanically distinct unit called a
chondron, which contains higher proteoglycan content6,7. The territorial matrix surrounds
the pericellular matrix and contains finer type VI collagen fibrils, while the more distant
interterritorial matrix has thicker collagen fibers and different associated molecules6,8,9.
In healthy cartilage, adult chondrocytes are responsible for producing the molecules that
make up the matrix. They are relatively quiescent, as they do not migrate and rarely
undergo mitosis10. Matrix turnover is low, with aggrecan in healthy cartilage having a
half-life of 25 years and collagen type II of 117 years11,12. Unusually, cartilage contains
no innervation or vasculature. Chondrocytes rely on the extracellular matrix for
mechanical protection and on diffusion through the fluid phase for nutrition. Thus, they
are also dependent on adjacent synovium and subchondral bone.

Synovium
The outer layer of the joint capsule is composed of dense irregular connective tissue
continuous with the periosteum. The outer joint boundary is continuous with the bone,
and the capsule provides strength and stability to the point of articulation. The inner
lining of the joint capsule, called the synovium, lines all non-cartilage surfaces in the
joint cavity. The synovial membrane itself can be divided into two major layers, the
intima and the subintima (Figure 1.2). The subintima is composed of loose connective
tissue and contains fibroblasts, relatively few immune cells, adipocytes, vasculature,
lymphatics,
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Figure 1.1. Zonal organization of articular cartilage.
Representation of the articular cartilage matrix with zones of chondrocyte and collagen
organization. Image courtesy of Netter Images © Elsevier Inc.
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Figure 1.2. Organization of synovium.
Representation of joint synovium with lining and sublining layers. Image reproduced
from Bertrand and Hubert 201413.
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and peripheral nerve terminals. The intima is the continuous lining layer directly in
contact with synovial fluid, which may contact but does not adhere to other joint surfaces
during motion. Although the lining is continuous with gap junctions, desmosomes, and
tight junctions, there is no basal lamina and the intima does not constitute a true basement
membrane14. Therefore, synovium is not a true epithelium, although it functions as a
barrier between the joint and the rest of the body. Nutrients, gases, and signaling
molecules from the circulation are filtered through endothelium and synovium,
collectively termed the blood-joint barrier, to reach synovial fluid and the cartilage
beyond.
Healthy synovial intima chiefly contains two major cell types: synovial macrophages and
synovial fibroblasts (classically named type A and type B synoviocytes, respectively)15.
Synovial fibroblasts contribute to joint lubrication through the production of hyaluronan,
long glycosaminoglycan polymers which maintain synovial fluid viscosity and water
content through local fluid forces16. Synovial macrophages, as part of the innate immune
system, monitor the joint environment and phagocytose the products of tissue turnover,
thereby maintaining homeostasis in the synovial joint. Within the synovial intima and
subintima, the total synovial macrophage population is composed of two distinct
populations: resident tissue macrophages and infiltrating macrophages. Resident
macrophages, like other tissue macrophages, arise from embryonic progenitors, are
present in the prenatal joint, and are capable of self-renewal17. Infiltrating macrophages
are derived from bone marrow precursors, first appear in the fetal joint perinatally, and
are terminally differentiated. In the healthy joint, resident macrophages predominate
relative to infiltrating macrophages from the periphery, with small populations of other
immune cells such as dendritic cells and T cells.
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1.2 Osteoarthritis
Due to the complexity of the synovial joint, there are numerous causes of synovial
arthropathy. Problems with individual or multiple joint tissues, in particular the
subchondral bone, cartilage, or synovium, or with systemic factors, can affect the health
and therefore the function of the joint. Osteoarthritis (OA) is the most common synovial
joint disease worldwide. Classically, OA is known as a disease resulting in the
destruction of articular cartilage, leading to permanent loss and pathological changes to
other joint tissues, with clinical manifestation of joint pain and disability18. With rising
prevalence and no disease-modifying treatment currently available, OA is a serious
global health problem and was elevated to the status of a “Serious Disease” by the United
States Food and Drug Administration in 2018.

Etiology
OA is most commonly a primary condition, but may also be secondary to anatomic
malalignment, trauma, or metabolic disorder. This classification system, originally
developed in the 1980s, is under review by the American College of Rheumatology in
light of new information about genetic and environmental factors19,20. Risk factors vary
by joint, but commonly include age, female sex, genetics, previous injury, and obesity
with or without additional components of metabolic syndrome21,22. Age is a particularly
strong risk factor, to the point where OA is commonly misperceived as a disease of
aging. The effect of aging is ascribed to a combination of increased chondrocyte
senescence, accumulated damage to the matrix, muscle weakness, hormonal changes (e.g.
menopause), and the long latency period of the disease23. Genome-wide association
studies have pointed to heritable risk in genes related to synovial joint formation (e.g.
GDF5), musculoskeletal structure and alignment (e.g. FRZB), and the molecular
components of the matrix itself (e.g. COL2A1, COMP)24. Obesity increases risk through
additional biomechanical strain on load-bearing joints and through metabolic syndrome,
which has many putative mechanisms including the induction of a pro-inflammatory
systemic state and altered adipokine signaling25.
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Pathobiology
Current theory suggests that OA results from either an acute insult to synovial joint
tissues or accumulated stress on articular cartilage. Through mechanical and/or molecular
signaling, chondrocytes are stimulated from their relatively quiescent state and respond in
various ways, including the production of inflammatory and catabolic factors (Figure
1.2).
Chondrocyte-mediated inflammatory responses include the induction of gene expression
and activation of intracellular processes that lead to production and release of fatty acid
mediators (e.g. prostaglandin E2 (PGE2)), reactive oxygen and nitrogen species (e.g. nitric
oxide), chemokines (e.g. interleukin-8 (IL-8)), and cytokines (e.g. interleukin 1 beta (IL1β), tumour necrosis factor-alpha (TNF-α))22. OA chondrocytes also produce, release,
and activate catabolic enzymes including matrix metalloproteinases (MMPs) and
aggrecanases. Matrix proteases degrade both aggrecan (e.g. a disintegrin and
metalloproteinase with thrombospondin-like motifs (ADAMTS) 4, 5) and collagen (e.g.
MMP1, 3, and 13)26. Particularly in early OA, these catabolic processes are accompanied
by anabolic responses from chondrocytes such as the induction of aggrecan and type II
collagen gene expression. However, the response is either inappropriate or insufficient to
adequately compensate, and the protein network is eventually permanently damaged8,27.
Early surface fibrillation of the matrix and proliferation of chondrocytes in the superficial
zone progresses to larger areas of matrix fissures and degradation, with loss of
chondrocytes21. This releases products (e.g. small leucine-rich proteoglycans, type II
collagen or aggrecan fragments) that further stimulate catabolic processes8,28.
Within deeper cartilage zones, chondrocytes undergo processes similar to those of
endochondral ossification. In this developmental program for bone formation,
chondrocytes die in an organized and controlled manner, leaving behind mineralized
matrix for osteoblasts to populate. In osteoarthritis, articular chondrocytes become more
hypertrophic, increase rates of apoptosis, and produce type X collagen, with the matrix
showing ectopic calcification and tidemark advancement and duplication29. Subchondral
bone, as a dynamic tissue, undergoes substantial remodelling throughout the course of
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Figure 1.3. Physiological changes in the osteoarthritic joint.
Diagram of a healthy versus osteoarthritic synovial joint with labels indicating changes to
joint tissue composition and common signaling molecules. Image reproduced from GlynJones et al. 201522.
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OA, with sclerosis, subchondral cyst formation, and osteophyte formation being the most
recognizable features30.
Synovium also plays a key part in OA pathogenesis. Even in early disease,
ultrasonography and arthroscopy can detect increased blood flow and synovial fluid
effusions20. Microscopic examination of biopsies reveals hyperplasia and villous growth
of the lining (fronding), infiltration by mononuclear leukocytes (macrophages, T cells, B
cells), angiogenesis, fibrosis, and edema31. Synovitis is undetectable in some cases, but
for the majority of OA patients, low-grade synovial inflammation persists31,32. The
presence of synovitis in OA has recently been identified as being clinically important. In
the knee and hand, synovitis generally becomes more prevalent with disease
progression33,34,35. In these joints, the presence of synovitis is also predictive of worse
radiographic damage and is strongly associated with greater joint pain35,36,37,38,39,40. Like
chondrocytes, synovial macrophages and fibroblasts also produce proteases (e.g. MMP3,
13) and various pro-inflammatory cytokines (e.g. IL-1β, interleukin-17 (IL-17), TNF-α),
chemokines (e.g. IL-8, monocyte chemoattractant protein 1), lipids (PGE2), and damageassociated molecular pattern molecules (DAMPs, e.g. S100a8, 9, high mobility group box
1 protein (HMGB1))21,32. On the other hand, synovial cells can release counter-regulatory
and protective molecules such as anti-inflammatory factors (e.g. interleukin-4,
interleukin-10, interleukin-1 receptor antagonist) and tissue inhibitors of
metalloproteinases (TIMPs, e.g. TIMP1, 2, 3)41. Finally, synovium produces growth
factors such as insulin-like growth factor 1, nerve growth factor, vascular endothelial
growth factor, and transforming growth factor-β (TGF-β) which are known in the
developmental context, but less so in disease. For example, TGF-β signalling is necessary
for articular cartilage homeostasis and preventing chondrocyte death, but is also involved
in synovial fibrosis and osteophyte formation in OA42,43. As there is relatively less
research available on the role of synovium in OA, the overall effect of synovitis on OA is
unclear.
Beyond the scope of this thesis, other joint tissues also appear to have roles in OA;
weakening of tendons and ligaments lead to laxity which may affect the balance of
biomechanical forces in the joint. Certain joints such as the knee have additional
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stabilizing structures. The meniscus, or articular disc, is a fibrocartilaginous structure
with its own biomechanical alignment and matrix physiology which can contribute to
OA44,45. The infrapatellar fat pad has been noted to express both pro- and antiinflammatory factors in knee OA, warranting further investigation in the field46,47.

Disease Burden
OA is an enormous health burden which grows every year due to rising disease incidence
and increasing rates of comorbidities that are themselves risk factors for OA. In the 2010
Global Burden of Disease Study, hip and knee OA was ranked as the 11th highest
contributor to global disability, more so due to pain than immobility48,49. In Canada, OA
currently affects 14% of adults over age 20 and is projected to affect over 10.4 million
people by 204050,51. Over the next two decades, direct costs on the healthcare system are
estimated to total $390 billion, and indirect costs $660 billion. Direct costs of health care
include physician visits, hospitalization, laboratory tests, drugs and mobility aids,
caregivers, and community resources, while indirect costs include lost work productivity
and unemployment for both patients and caregivers52.
OA is a major cause of reduced quality of life. A recent study in the United States
estimated 1.857 quality-adjusted life-years (QALY) lost per knee OA patient, which
nearly doubled to 3.501 QALY for patients who were also obese53. The difference may
be greater still for patients with OA in other joints and other comorbidities. In addition to
physical pain, fatigue, and physical limitations, OA patients may experience distress, low
mood, sleep difficulties, and anxiety54,55,56. For people living with OA, losing the ability
to live with autonomy and free of pain is the greatest threat from OA.

Disease-Modifying Treatment for OA
There is currently no disease-modifying treatment approved for human patients. OA
treatment focuses on symptom management to maintain participation in activities of daily
living57,58,59,60. Patient self-management and education, as highly accessible and costeffective modalities, are recommended for all patients20,61,62. Exercise for musculoskeletal
strength and weight management has been shown to improve pain, aching, and stiffness,
thereby reducing disability63. Non-steroidal anti-inflammatory drugs and acetaminophen

12

are the most abundant pharmacological recommendations for OA symptoms.
Intraarticular corticosteroids are also effective at reducing pain in knee OA, but effects do
not persist, and steroid injections are not recommended for hand OA64. In a minority of
cases where focal damage is detected early, surgical interventions to replace the matrix
with transplanted autologous cartilage, progenitor cell-generated fibrocartilage, or
artificial bioscaffolding have been used, but these are not routine options22. Rather,
arthroplasty is the surgical treatment of choice that is used to relieve severe symptoms at
the end stage of disease. Unfortunately, this means that effective therapy is not available
to many patients who suffer for many years in wait for joint replacement. The risks of
surgical operation, revisions, and implant replacement later in life make this option far
from ideal.
Similar to treatment for rheumatoid arthritis, an autoimmune disease that also directly
damages synovial joints, pathological processes have been pharmacologically targeted in
OA. Several categories of molecular targets, including various MMP inhibitors (e.g.
doxycycline), inflammatory mediator blockers (e.g. adalimumab, anakinra), and
recombinant growth factors (e.g. fibroblast growth factor 18), have been tested, but no
therapy has been approved as a disease-modifying treatment for OA65. As repairing tissue
damage in a highly inflammatory environment is difficult, a combination of treatments
for preventing further damage, repairing existing damage, and inhibiting the progression
of inflammation may ultimately be needed.

Animal Models of OA
Synovial joints are conserved in all mammals; synovial joints have a highly similar
morphology despite differences in animal size, weight, and number of legs. A wide
variety of animal models is available for OA research, including the mouse, rat, rabbit,
dog, sheep, cow, and horse, among others. Larger animals, such as the horse and sheep,
are advantageous for studying surgical induction and interventions, and they provide
more biological material for data collection66. Small animals are more difficult to image
and may not be as translatable to human patients due to phylogenetic differences in
physiology and biomechanical loading. However, they have lower care costs, age more
quickly with experimental OA progression, and are highly suitable for use in drug
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screening and genetic modeling studies. Pain and gait changes remain challenging to
interpret in all species, although recent work in the OA field has advanced some of the
available tools for measuring pain-related behavior in small animal models, especially
rodents67. Primary OA is found to spontaneously develop in the mouse, rat, dog, and
horse with age, while secondary OA models can induce disease via surgical insult to the
joint, non-invasive impact injury, ovariectomy, or intraarticular injection of toxins or
enzymes.
For this thesis, we selected a post-traumatic rat model, with OA secondary to
destabilization of the stifle joint via surgical transection of the anterior cruciate and
medial meniscotibial ligaments (ACLT-DMM). Animal intervention and care protocols
were based off previous studies using a similar model of joint destabilization via anterior
cruciate ligament transection and partial medial meniscectomy (ACLT-pMMx), which
resulted in progressive damage to articular cartilage of the operated knee (Figure 1.4)68,69.
We predicted that in the ACLT-DMM model, changes due to early OA would present at
4 weeks post-surgery, and that disease progression would be similar to the ACLT-pMMx
model, with moderate to severe disease evident at 12 weeks post-surgery.
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Figure 1.4. Articular cartilage damage increases over time in the ACLT-pMMx rat
model.
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a) OARSI histopathology scores for tibial and femoral articular surfaces in ipsilateral and
contralateral joints from rats given ACLT-pMMx surgery and in ipsilateral joints from
rats given sham surgery (control) over 20 weeks post-surgery (mean ± SEM, n = 4).
Animals were also subjected to forced mobilization (FM) or nonmobilized (NM)
treatment. Significantly different means at each time point are indicated by different
letters (one-way ANOVA with Tukey’s post hoc test, p < 0.05). b) Representative
micrographs at the same magnification of sagittal sections stained with safranin-O, fast
green, and hematoxylin at these timepoints show disruption of the normal articular
surface (ac), including surface discontinuity (arrow), vertical fissures (arrowhead),
delamination (del), chondrocyte clustering (cc), denudation (dn), sclerotic bone (sb)
fibrocartilage-like tissue (fc), and subchondral plate failure (pf). Figure adapted from
Appleton et al. 200766.
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1.3 Research Question
Synovitis has recently been recognized as a clinically important feature in patients with
OA due to the association of synovitis with pain and structural disease progress,
particularly in knee OA. Synovitis results in the production of several inflammatory
mediators that can directly impact other joint tissues including cartilage. Synovitis is also
present in patients with early OA and becomes more severe with disease progression,
making it an attractive target for treatments used in early (pre-surgical) stages of OA. In
this thesis, we investigated the role of synovitis in OA and the effect of synovium on
cartilage. In particular, we sought to determine if synovitis in early knee OA is able to
stimulate articular cartilage and whether the effects of early OA synovium are harmful or
protective to articular chondrocyte physiology.

Rationale
The synovium supports cartilage health and function in healthy joints, but its role in early
OA development is not well understood. There is urgent need for disease-modifying
treatment. Developing an intervention in early OA to prevent joint damage and other
pathological changes is preferable. Therefore, studying synovium in early OA will
expand our understanding of the disease and possibly provide opportunity for
intervention. Synovial macrophages in OA synovium have not been extensively
investigated, but their status as effector cells of the innate immune system and the current
literature suggest they have important signaling roles. A surgically induced posttraumatic rat model of OA has previously been established and is suitable for evaluating
joint physiology and potential interventions for macrophages.

Hypothesis
Early experimental PTOA synovium alters healthy chondrocyte physiology, inducing
pro-inflammatory and pro-catabolic effects. Additionally, manipulating synovial
macrophages in early PTOA via depletion or inhibition of polarization pathways will
modify PTOA outcomes in synovium and cartilage.
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Objective
Our overall objective is to investigate the effect of OA synovium on chondrocytes and
joint outcomes using a rat model of PTOA (Figure 1.5). Specifically, we will:
1. Establish an in vitro co-culture system to study synovium-chondrocyte
interactions (Chapter 2)
2. Assess the effect of PTOA synovium on chondrocytes and compare early
and later stage PTOA synovium (Chapter 2)
3.

Investigate the effect of manipulating synovial macrophages on
chondrocyte and joint outcomes (Chapter 3).
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Figure 1.5. Schematic of research objectives.
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Chapter 2
A novel ex vivo joint co-culture system for investigating
synovium-chondrocyte interactions demonstrates protective
effects of synovium in early experimental osteoarthritis.
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2.1 Chapter Summary
Osteoarthritis (OA) is a degenerative joint disease with rising burden and no diseasemodifying drug available. The impact of the synovial tissue on cartilage in OA is not
fully understood but may be a strategic therapeutic target. Co-culturing synovial tissue
and primary articular chondrocytes obtained from a rat model of post-traumatic knee OA
(PTOA) allows us to directly assess chondrocyte responses to synovial signalling. This
study optimized conditions of a novel in vitro joint model and evaluated the effects of
synovium from experimental PTOA joints on naïve chondrocytes.
Whole-joint synovial tissue from early (4 weeks post-PTOA induction) or later (12
weeks) stage OA, or time-matched controls (surgery-naïve or sham surgery), was placed
into a transwell system with adult rat primary articular chondrocytes grown in highdensity monolayer. Conditioned medium was collected to measure sulfated
glycosaminoglycan secretion and chondrocyte RNA was isolated for gene expression
analysis.
Early PTOA synovium induced increased sulfated glycosaminoglycan secretion,
decreased Col2a1 expression, and increased Mmp3 and Prg4 expression in primary
articular chondrocytes compared to controls. These effects were lost with later stage
PTOA synovium, which only decreased Ccl2 expression in chondrocytes.
In conclusion, early PTOA synovium induces changes in chondrocyte physiology that
include regenerative responses, whereas later stage PTOA synovium does not induce
these effects.
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2.2 Introduction
Osteoarthritis (OA) is one of the most urgent global health problems1,2. In Canada, OA is
projected to affect over 1 in 5 people by 20253. OA typically affects major joints,
especially the hip, knee, spine, and hand. As a disease of the whole joint, OA causes
pathological changes in all joint tissues, including cartilage, synovium, subchondral bone,
meniscus, muscle, tendon, and ligament4. OA patients suffer joint pain, reduced function,
and disability, but there is no treatment approved to prevent progression to end-stage
disease. Evidence-based treatments for OA are only partially effective for management of
symptoms, such as pain and stiffness, but cannot slow or reverse disease damage5,6.
Patients with end-stage disease usually require surgery to replace failing tissues with an
implant. While highly effective for a majority of patients, full recovery times from
surgery routinely exceed one year and patients experience wide variation in post-surgery
outcomes, which are partially influenced by functional ability and comorbid conditions,
and some patients require additional revision or implant replacement6,7,8,9. Conceptually,
early stage medical treatment of OA is therefore an ideal approach to prevent disease
progression before radiographic joint damage and loss of function occur10,11. Our
understanding of the earliest events in OA pathophysiology is limited. Primary OA is
idiopathic, while secondary OA follows previous post-traumatic, congenital,
biomechanical, or metabolic derangements. Secondary forms of OA are typically easier
to model, especially in animals, but share several pathophysiologic and morphologic
features with primary OA12. Research remains focused on cartilage above other joint
tissues.
Cartilage is the site of much change through progression of the disease; when abnormal
stresses are applied, chondrocytes rouse from a quiescent state to actively proliferate and
produce increased levels of matrix proteins and proteases13,14. Catabolic and
inflammatory processes damage the matrix over time, with limited regeneration due to
the absence of innervation and vasculature that trigger the normal healing sequence in
other tissues. As the disease progresses, more chondrocytes become affected and
eventually undergo terminal hypertrophy. In late-stage OA, the once-populated cartilage
erodes away to underlying bone which articulates poorly.
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Synovium is a structurally and functionally heterogenous tissue responsible for
maintaining the homeostasis of all joint tissues, including joint cartilage. Synovium
provides lubrication by producing synovial fluid, clears debris from the joint cavity,
supplies nutrition to cartilage and other joint tissues, and monitors the joint environment
for infection and other disturbances15. As synovitis has only recently been recognized as a
key feature of OA, our understanding of the physiology and roles of the synovium is far
from complete16. The process by which synoviocytes become activated in early OA is
unknown, but likely involves matrix breakdown products and inflammatory signals from
cartilage17. Synovitis is found in a majority of early and late OA patients, and presents
with greater severity in later stages of OA18,19. In the knee, clinical studies have shown
strong correlation between synovitis and greater pain16,20,21. The presence of synovitis is
predictive of knee OA incidence and progression and hand OA
progression16,22,23,24,25,26,27,28,29. Knee synovitis is heterogenous and may appear in any
area, but certain patterns are more frequent and have been linked to differences in pain 30.
Synovial production of catabolic and pro-inflammatory factors such as matrix
metalloproteinases (MMPs) and tumour necrosis factor-alpha (TNF-α) further suggests a
pathogenic role, but anti-inflammatory mediators are also produced by OA synovium.
Adding further uncertainty to the role of synovium in OA, clinical trials blocking
inflammatory factors such as TNF-α and interleukin-1 beta have not sufficiently shown
therapeutic effect31,32. Ongoing trials using anti-inflammatory factors such as interleukin4 or interleukin-10 have shown promising preliminary results33,34. Another promising
biologic, recombinant fibroblast growth factor 18, produced anabolic effects on cartilage
but no effect on pain and stiffness in clinical trials, indicating that treating cartilage
damage alone is insufficient35. Changes in levels of other growth factors such as nerve
growth factor and transforming growth factor-β (TGF-β) superfamily proteins have also
been noted in OA36,37. TGF-β1, which induces expression of matrix proteins and prevents
chondrocyte hypertrophy, is affected by and affects inflammatory signals in the joint37,38.
Synovitis is clearly an important feature in OA, but its impact on surrounding joint
tissues such as articular cartilage is not well understood. Furthermore, there is little
contextual information regarding potential differences in the functions of synovium at
different stages of OA. Since early OA potentially presents the best strategic window for
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introduction of medical treatment for OA, it is particularly important to understand
synovium-cartilage interactions during OA development. In this study, we assess the
effect of synovium from early and later stage OA joints on primary articular
chondrocytes. By integrating in vitro chondrocyte cultures with ex vivo synovial tissues
from an established rat model of experimental post-traumatic OA (PTOA), we establish a
new model of intraarticular signaling to test our overall hypothesis that synovium from
early PTOA joints induces pro-inflammatory and catabolic changes in chondrocytes.
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2.3 Materials and Methods
Reagents
Chemical reagents and histology supplies were purchased from Fisher Scientific or
MilliporeSigma unless otherwise specified. Cell and tissue culture media were purchased
from Gibco, while tissue culture plastics were from BD Falcon. RNA isolation reagents
were purchased from Invitrogen. PCR reagents and equipment, including analysis
software, were all supplied by Bio-Rad.

Experimental PTOA rat model
All experiments were performed according to the Animal Use Protocol approved by the
institutional Animal Care Committee (Appendix A). Outbred Sprague-Dawley rats (strain
code 400) were purchased from Charles River Canada and fed a standard chow diet ad
libitum. Following a previously established protocol, surgery was performed on the right
knees of 12-week-old male rats39,40. Female rats were not included in this study due to the
known influence of sex hormones on OA, and to simplify experimental logistics. Briefly,
animals were given prophylactic ampicillin and buprenorphine for post-procedure
analgesia subcutaneously. Anesthesia was induced with isoflurane gas. PTOA was
induced by incising the medial aspect of the anterior joint capsule to open the right knee
joint, transecting the anterior cruciate ligament and the medial meniscotibial ligament at
its attachment to the meniscus, and closing the joint capsule with absorbable sutures.
Sham surgery was performed on age-matched animals by opening and closing the joint
capsule only. Animals did not undergo forced mobilization and were allowed to recover
with monitoring in home cages. Surgery-naïve control animals were also age-matched.
Only the operated right knee joints were experimentally compared, as changes in joint
tissue physiology occur in the contralateral knee joint and may confound interpretation of
results40. This protocol induces OA-like disease at a timeline and severity comparable to
similar surgical models (data not shown).
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Cell and tissue cultures
Knee joint tissues were collected by gross dissection. Overlying skin, muscle, and tendon
were removed from legs before opening the joint under sterile conditions.
Primary articular chondrocytes were collected from healthy, surgically-naïve 16-weekold male rats. Femoral and tibial articular surfaces were shaved using a scalpel, carefully
excluding contamination by periosteum, meniscus, or bone tissues. Cartilage from
multiple joints was pooled in Dulbecco’s Modified Eagle Medium, low glucose, with Lglutamine (DMEM), minced into pieces of approximately 1 mm3, and placed into DMEM
with 10% fetal bovine serum (FBS), 1% Antibiotic-Antimycotic, 800 U/mL collagenase
II, and 100 U/mL DNase I for 2 hours at 37C with variable agitation on a Miltenyi Biotec
gentleMACS Dissociator. The resulting suspension was triturated, passed through a 70
µm cell strainer and washed with primary chondrocyte medium (1:1 DMEM/Ham’s F12,
low glucose, L-glutamine, with 10% FBS and 1% penicillin-streptomycin). Live cells
were counted on a Bio-Rad TC20. P0 chondrocytes were initially seeded at 10% density
into 12-well plates, one well per joint, in primary chondrocyte medium, with medium
changes every 2-3 days until confluent. For expansion into stocks, P0 chondrocytes were
seeded at 2-5% in T75 flasks in primary chondrocyte medium, with medium changes
every 2-3 days until confluent. Expanded P0 chondrocytes were trypsinized, gradually
frozen to -80C in FBS with 10% DMSO, and stored in liquid nitrogen.
Knee joint synovium was dissected over ice-cold DMEM with care to keep the tissue
intact. After opening the joint by cutting around the suprapatellar region, the menisci and
patella were removed, and synovium was peeled away from the outer fibrous capsule.
Preliminary experiments used the mixed population of synoviocytes isolated by placing
minced synovium in DMEM with 10% FBS, 1% Antibiotic-Antimycotic, 100 U/mL
collagenase IV, and 100 U/mL DNase I for 1 hour at 37C with variable agitation on the
gentleMACS Dissociator. The digest suspension was passed through a 70 µm cell
strainer, washed with DMEM with 10% FBS and 1% penicillin-streptomycin, and seeded
at 10% in 12-well transwell inserts, 0.4 µm pore size. For subsequent experiments using
whole synovial tissue in co-culture, all synovium from a single joint was placed into a

31

seated 12-well transwell insert with serum-free 1:1 DMEM/F12 with 1% penicillinstreptomycin in both chambers per replicate (n = 1).
To set up co-cultures, P0 chondrocytes were grown as described above, while P1
chondrocyte aliquots were thawed from frozen stocks, washed with primary chondrocyte
medium, seeded at 10% density into 12-well plates, and expanded until confluent. Prior
to the start of the culture period, chondrocytes were serum-starved overnight (8 to 16
hours) and synovial tissue was placed into serum-free medium for 24 hours. Co-cultures
were assembled by transferring the synovium-conditioned medium from the lower
chamber onto the serum-starved chondrocytes and placing the transwell insert with
synovium and conditioned medium on top (Figure 2.1).

Tissue histology and immunohistochemistry
Synovial tissue from co-cultures were fixed in 4% paraformaldehyde overnight,
processed, and embedded in paraplast (Leica Biosystems). Tissue sections were cut at 5
thickness and collected on Superfrost Plus slides (Fisher). H&E slides were stained with
Harris Hematoxylin and 0.25% Eosin Y and mounted with Cytoseal XYL (Richard-Allan
Scientific) under no.1 coverslips (VWR). Tissues used for immunofluorescence
experiments underwent antigen retrieval by immersion in 10 mM Tris, 1 mM EDTA,
10% glycerol buffer heated to 70C and allowed to cool to room temperature, were
blocked with 1% bovine serum albumin (GE Healthcare), 0.1% Triton X-100 in PBS, and
probed with rabbit anti-cleaved caspase-3 primary antibody (Abcam ab49822) diluted
1:1000 in blocking buffer, followed by AlexaFluor488-conjugated goat anti-rabbit
secondary antibody diluted 1:500 in blocking buffer, then mounted with ProLong Gold
Antifade Mountant with DAPI. Slides were imaged on a BioTek Cytation 5 multi-mode
imager.

Dimethylmethylene blue (DMMB) assay
Conditioned medium from co-cultures was assayed for sulfated glycosaminoglycan
(sGAG) content using a protocol based on previously described methods41,42. In
microwell plates, 200 µL DMMB reagent (38.46 mmol 1,9-dimethyl-methylene blue zinc
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Figure 2.1 Experimental timeline for synovium-chondrocyte co-cultures.
Synovium from joints 4 or 12 weeks post joint destabilization surgery, sham surgery, or
no surgery were collected into serum-free medium. Simultaneously, chondrocytes were
expanded to confluency. Synovium and chondrocytes were then co-cultured.
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chloride, 40.5 mmol glycine, 27.38 mmol sodium chloride, 9.5mmol acetic acid
(Bioshop)) was combined with 100 µL of conditioned medium or chondroitin sulfate
standards diluted to the appropriate range in serum-free chondrocyte medium in triplicate
and read immediately at absorbance wavelength 595 nm with reference wavelength 655
nm on a Safire plate reader (Tecan Life Sciences).

RNA isolation and gene expression analysis
We made efforts to adhere to the minimum information for publication of quantitative
real-time PCR experiments (MIQE) guidelines where possible regarding controls for
contamination and technical error43.
Co-cultured chondrocytes were lysed by adding TRIzol to each well and triturating.
Samples were transferred to phase separation tubes, combined 5:1 with chloroform,
shaken for 50 seconds, and centrifuged at 12000 x g for 15 minutes at 4C. The RNEasy
Mini Kit (QIAGEN) was used following instructions for subsequent steps. The aqueous
phase was combined with an equal volume of 70% ethanol and transferred onto silicaspin
columns, followed by on-column DNase I digestion, washes, and elution into nucleasefree water. Eluted RNA yield and purity was measured on a Nanodrop 2000 (Thermo
Scientific). Samples were reverse transcribed using iScript Reverse Transcription
Supermix following manufacturer thermal cycle recommendations. Quantitative real-time
PCR (qPCR) was performed by combining SsoAdvanced Universal SYBR Green
Supermix, predesigned primers (Table 2.1), and cDNA template in triplicate. Template
per reaction varied by gene. Plates were thermocycled as follows: an initial polymerase
inhibitor removal step at 95C for 30 s, a repeating denaturation step at 95C for 15 s
followed by an annealing and elongation step at 60C for 30 s for 40 cycles, with an
ending melt-curve analysis from 65C to 95C in 0.5 C steps at 2 s/step. Cq values were
calculated on CFXMaestro 1.1 and normalized to reference genes Rpl13a and Rplp0,
except where usage of only Rpl13a is noted. Reference genes were selected prior to target
gene assessment using the Bio-Rad pre-designed rat reference gene panel with
representative samples (n = 3) and CFXMaestro Reference Gene Selector tool.
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Table 2.1. Reference information for Bio-Rad PrimePCR™ PCR primers.
Gene
Acan
Adamts5
Ccl2
Col10a1
Col2a1
Il6
Il17a
Mmp13
Mmp3
Prg4
Rpl13a*
Rplp0*
S100a8
Sox9

Amplicon
Context Sequence
1:141780455-141787109
11:29043239-29056911
10:69048547-69048678
20:42913429-42916882
7:139647809-139647911
4:3095863-3097287
9:25698119-25699513
8:5531849-5533218
8:5689395-5691167
13:72640183-72642005
1:102186223-102186424
12:48589001-48589127
2:209508182-209508274
10:100968094-100968214

* denotes a reference gene.

Transcription
intron-spanning
intron-spanning
exonic
intron-spanning
exonic
intron-spanning
exonic
intron-spanning
intron-spanning
intron-spanning
exonic
exonic
exonic
exonic

Amplicon
Length
109
120
102
120
73
120
106
87
66
118
87
97
63
91
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Initial gene analysis experiments used droplet digital PCR (ddPCR) for its high
sensitivity and precision, but unexpected permanent equipment failure necessitated a
return to traditional qPCR. ddPCR was performed by combining QX200 ddPCR
EvaGreen Supermix, predesigned primers (Table 2.1), and cDNA template. Template per
reaction varied by gene and was diluted to allow optimal digital analysis. Droplets were
generated from 20 µL reaction mixes on the AutoDG Automated Droplet Generator, then
immediately thermocycled with the following steps: 95C for 5 min, 95C for 30 s
followed by 60C for 1 min for 45 cycles, 4C for 5min, and 90C for 5 min before holding
at 4C, with all steps ramped at 2 C/s. Droplets were read and gated using QuantaSoft™
Analysis Pro 1.0. Absolute copy numbers were normalized to reference genes Rpl13a and
Rplp0 for comparison.

TGFBR1 inhibition and FOXO1 inhibition assays
SB 431542 is a well-established selective small molecule inhibitor of the TGF-β type I
receptor (TGFBR1)44. AS 1842856 is a relatively new small molecule inhibitor of
forkhead box O1 (FOXO1)45. To determine the minimum effective concentration for both
drugs in vitro, P1 primary chondrocytes were grown to confluency in a 96-well plate,
serum-starved overnight, pre-incubated with inhibitors (dissolved in DMSO vehicle) or
DMSO only (control), diluted in serum-free medium for 1 hour, then stimulated with 10
ng/mL TGF-β for 24 hours. Cells were collected in TRIzol for mRNA isolation and
qPCR analysis of Prg4 expression relative to Rpl13a as described above.
For inhibition of TGFBR1 signalling in co-culture conditioned medium, P1 primary
chondrocytes were again grown to confluency in 96 well plates and serum-starved. Cells
were pre-conditioned with 1 µM SB 431542 or DMSO for 1 hour. Conditioned medium
samples were thawed to room temperature from -20C storage, combined with inhibitor in
DMSO vehicle or vehicle only, and applied to the well with minimal dilution (150 µL
neat medium to 5 µL drug in serum-free medium) for 24 hours before collection for gene
expression analysis.

36

Statistics
All data was analyzed using GraphPad Prism 8.2.1. Type I error threshold for all analyses
was set at α = 0.05. One-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparisons test was used for sGAG secretion and gene expression over a
timecourse (comparisons between 24h, 48h, 72h, and 96h) in P1 chondrocytes cultured
alone in serum-free medium. One-way ANOVA followed by Dunnett’s multiple
comparisons test was used for the effects of synovium PTOA condition (comparisons
between naïve, sham, and PTOA synovium) on chondrocytes and for the effects of
TGFBR1 and FOXO1 inhibitors (comparisons between multiple concentrations of
inhibitor and DMSO vehicle) on chondrocyte Prg4 expression. An unpaired two-tailed ttest was used for the effect of TGF-β (comparison between TGF-β and PBS control) on
chondrocyte Prg4 expression. Two-way ANOVA followed by Sidak’s multiple
comparisons test was used for TGFBR1 inhibitor and conditioned medium treatment
(comparisons between TGFBR1 inhibitor and DMSO vehicle with naïve, sham, or PTOA
co-culture conditioned medium) on chondrocytes.
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2.4 Results
P0 articular chondrocytes express baseline inter-individual variation
Preliminary primary cell co-cultures used P0 articular chondrocytes collected from
multiple donor animals, where chondrocytes from a single donor animal were used in a
single co-culture replicate. Each chondrocyte culture from one donor animal was grown
to 70% confluency before being placed into co-culture with dissociated primary
synoviocytes, also from one donor per culture, in serum-free medium for 48 hours. These
co-cultures showed variable levels of sGAG secretion within groups, with no significant
differences between treatments (Figure 2.2a). Moreover, sGAG levels were below
expected values based on previous studies of adult primary chondrocytes in monolayer
culture46. We revised our approach and grew chondrocytes to 90-100% confluency before
co-culture under the same conditions. This resulted in higher sGAG levels than before,
but values were still lower than expected (Figure 2.2b). No significant differences
between treatments were found for these cultures.
Preliminary 48-hour co-cultures using P0 chondrocytes grown to 70% confluency
showed no significant differences in expression of all chondrocyte genes of interest
assayed (Acan, Adamts5, Ccl2, Col2a1, Col10a1, Il6, Mmp3, Mmp13, S100a8, Sox9)
between treatments (Figure 2.3). We switched from standard real-time qPCR to ddPCR to
improve detection sensitivity for low-copy genes to assay select genes for revised cocultures using chondrocytes grown to 100% confluency, but this did not reduce the interindividual variation between donors observed (Figure 2.4).

P1 articular chondrocytes maintain a chondrocyte-like phenotype
Preliminary experiments (2.4.1) indicated that P0 primary chondrocytes demonstrate a
high degree of inter-individual variability in sGAG release and gene expression. Since
our experimental design sets the synovium from each PTOA condition as the independent
variable with chondrocyte response as the dependent variable, we elected to assess
pooled primary articular chondrocytes from multiple donors for all co-cultures instead of
using chondrocytes from one joint per co-culture. Thus, we expanded P0 chondrocytes
pooled from multiple naïve joints into a large stock of P1 chondrocytes. Morphologically,
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DMMB Assay for sGAG Content in Conditioned Medium
DMMB Assay for sGAG Content in Conditioned Medium
from Naive Chondrocytes Grown in 48hr Co-culture with Mixed
Synoviocytes
from
Naive Chondrocytes Grown in 48hr High-density Co-culture with Mixed Synoviocytes
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b)

2.0
1.5
1.0
0.5
0.0

2.5

[sGAG] (g/mL)

[sGAG] (g/mL)

a)

2.0
1.5
1.0
0.5

Naive

Sham

OA

Synovium

0.0

Naive

Sham

OA

Synovium

Figure 2.2. sGAG content in conditioned medium from P0 chondrocytes co-cultured
with dissociated primary synoviocytes.
P0 primary articular chondrocytes were co-cultured at a) 70% confluency and b) 100%
confluency with expanded primary synoviocytes dissociated from age-matched surgerynaïve, surgical sham, and 4W PTOA knee synovium for 48 hours. Conditioned medium
was collected and measured for sGAG content by DMMB assay (mean ± 95% CI, n = 46).
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Figure 2.3. Gene expression in P0 chondrocytes co-cultured at 70% confluency with
dissociated primary synoviocytes.
P0 primary articular chondrocytes were co-cultured at 70% confluency with expanded
primary synoviocytes dissociated from age-matched surgery-naïve, surgical sham, and
4W PTOA knee synovium for 48 hours. qPCR analysis of gene expression levels is
displayed as fold change (mean ± 95% CI, n = 6).
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Figure 2.4. Gene expression in P0 chondrocytes co-cultured at confluency with
dissociated primary synoviocytes.
P0 primary articular chondrocytes were co-cultured at 100% confluency with expanded
synoviocytes dissociated from age-matched surgery-naïve, surgical sham, and 4W PTOA
knee synovium for 48 hours. ddPCR analysis of gene expression levels is displayed as
fold change (mean ± 95% CI, n = 4).
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P1 cells resembled P0 cells, with broad triangular cell bodies during expansion and a
more compact, granular “cobblestone” appearance at confluency (Figure 2.5), consistent
with the literature47,48. Highly confluent monolayer cultures of P1 chondrocytes secreted
sGAGs over time in a linear fashion similar to P0 chondrocytes, with significantly higher
concentrations in the conditioned medium at 120 hours than at 24 hours (Figure 2.6). P1
chondrocyte expression of Acan, Col2a1, Prg4, Runx2, and Sox9 did not significantly
differ between timepoints, although Prg4 appears to decline over time (Figure 2.7).

Synovial tissue remains viable in serum-free culture
Synovial tissue culture in standard conditions (FBS-supplemented medium, 37C, 5%
CO2) has previously been described49,50. As our initial experiments with high density P1
primary articular chondrocytes did not demonstrate a clear response to co-culture with
dissociated expanded primary synoviocytes, we decided to use whole synovial tissue
from a single knee joint for each co-culture. Rather than isolating synoviocytes, whole
synovial tissue culture minimizes cell loss and ex vivo selection bias against synovial cell
populations that are relatively more sensitive to enzymatic and mechanical tissue
dissociation. Co-cultured synovium explants were fixed after 48 hours ex vivo and
processed for histology to ensure cellular viability during the culture period. Sections
stained with H&E found regular synovial tissue organization with no signs of diffuse or
focal cell death such as cell swelling and rupture or nuclear condensation and
fragmentation51 (Figure 2.8a). Sections stained with DAPI and anti-cleaved caspase-3
antibody found very few positive apoptotic cells with random distribution through the
tissue (Figure 2.8b).

Early PTOA synovium induces changes in primary articular
chondrocyte physiology
To test the effects of early PTOA synovium on articular chondrocytes, we co-cultured
synovial tissue explants from rat knees with P1 primary articular chondrocytes in
monolayer culture. Co-culture for 24 hours with 4W PTOA synovium caused
significantly increased sGAG secretion into conditioned medium compared to naïve
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Figure 2.5. Morphology of P1 chondrocytes during expansion in monolayer culture.
Representative phase-contrast micrographs of P1 adult articular chondrocytes expanded
in monolayer culture at a) 10% confluency and b) 100% confluency. Bar represents 100
µm.

43

Figure 2.6. sGAG content in conditioned medium from P1 chondrocytes in serumfree conditions without synovial co-culture.
Confluent P1 primary articular chondrocytes were cultured in serum-free medium alone
for up to 120 hours. Conditioned medium was collected and measured for sGAG content
by DMMB assay (mean ± 95% CI, n = 4, *p < 0.05).
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Figure 2.7. Gene expression in P1 chondrocytes in serum-free conditions without
synovial co-culture.
Confluent P1 primary articular chondrocytes were cultured in serum-free medium alone
for up to 120 hours. qPCR analysis of gene expression levels is displayed as ΔCq (mean
± 95% CI, n = 4).
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Figure 2.8. Viability of synovial tissue after 48 hours in serum-free co-culture with
primary chondrocytes.
Representative micrographs of sections of synovial tissue after 24 h alone in serum-free
culture followed by 24 h in co-culture with primary articular chondrocytes, with a) H&E
staining with inset for tissue microstructure and general cell appearance and b)
immunofluorescence with DAPI and anti-cleaved caspase-3 (n = 5). Bar represents 100
µm.
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synovium controls (Figure 2.9a). Sham control synovium values were intermediate but
not statistically different from naïve control values.
In gene expression analyses, 4W PTOA synovium also stimulated significantly decreased
levels of Col2a1, Il17a, S100a8 levels and significantly increased Mmp3 and Prg4
compared to control (Figure 2.10). Sham surgery synovium also caused significantly
decreased Col2a1, Il17a, and S100a8 levels, as well as decreased Acan. These results
suggest that surgical effects on synovium persist at 4 weeks post surgery in this model,
but PTOA-specific effects are also detectable by this time.
We also measured these effects after a longer co-culture duration of 120 hours to
determine whether chondrocytes responses are sustained. At 120 hours, 4W PTOA
synovium continued to cause further increases in sGAG secretion (Figure 2.9b).
Chondrocyte gene expression changes induced by PTOA appeared to have equilibrated,
although Acan and Sox9 levels were significantly lower for sham synovium and appear
lower for PTOA, but not significantly different (Figure 2.11).

Later stage PTOA synovium alters Ccl2 expression in primary articular
chondrocytes
The development of PTOA and disease progression result in changes in synovial
physiology. To compare the effects of early PTOA synovium on chondrocytes versus
synovium from a later stage of PTOA, we co-cultured primary chondrocytes with
synovium from PTOA joints collected 12 weeks after surgery, compared with agematched sham surgery and surgically naïve controls. Interestingly, no significant
differences were found between PTOA synovium and controls in sGAG secretion (Figure
2.9c). Similarly, aside from a significant decrease in Ccl2 expression from naïve
synovium to PTOA and sham synovium treatments, no other significant differences in
chondrocyte gene expression were found (Figure 2.10). In this experimental model,
cartilage damage is well established at 12 weeks PTOA, compared to the minor damage
at the 4 week timepoint39.
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Figure 2.9. sGAG content in conditioned medium from P1 chondrocytes co-cultured
with synovial tissue.
P1 chondrocytes were co-cultured a) for 24 hours with 4W PTOA synovium, b) for 120
hours with 4W PTOA synovium, or c) for 24 hours with 12W PTOA synovium.
Conditioned medium was collected and measured for sGAG content by DMMB assay
(mean ± 95% CI, n = 4-5, *p < 0.05).
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Figure 2.10. Gene expression in P1 chondrocytes co-cultured with synovial tissue for
24 hours.
Confluent P1 articular chondrocytes were co-cultured for 24 hours with synovium from
4W and 12W PTOA joints, sham controls, or surgery-naïve controls. qPCR analysis of
gene expression levels is displayed as ΔCq (mean ± 95% CI, n = 5, *p < 0.05).
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Figure 2.11. Gene expression in P1 chondrocytes co-cultured with synovial tissue for
120 hours.
Confluent P1 articular chondrocytes were co-cultured for 120 hours with 4W PTOA
synovium. ddPCR analysis of gene expression levels is displayed as absolute copy
number relative to the average of two reference genes per µg of template (mean ± 95%
CI, n = 4, *p < 0.05).
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Effects of early PTOA synovium on primary articular chondrocytes is
not fully replicated by conditioned medium transfer
PRG4, also known as lubricin or superficial zone protein, is a lubricating glycoprotein
that is protective against OA development when overexpressed in mouse models,
partially through its inhibitory effect on chondrocyte catabolism and hypertrophy52. Thus,
the upregulation of Prg4 in our co-culture model and the mechanism responsible are
potentially beneficial in OA. TGF-β1has previously been shown to induce Col2a1, Acan,
and Prg4 expression in rat articular chondrocytes and Prg4 additionally in bovine
chondrocytes38,53,54,55. Similarly, FOXO1 regulates Prg4 in murine articular chondrocytes
and chondrogenic ATDC5 cells56. We wanted to determine if the induction of Prg4 in
chondrocytes stimulated by 4W PTOA synovium was mediated by TGF-β signaling
and/or FOXO1 activity. TGF-β (10 ng/mL) was used to stimulate P1 chondrocytes in
confluent monolayer culture, which resulted in increased Prg4 expression (Figure 2.12).
Next, the minimal inhibitory concentration of SB 431542, a TGFBR1-selective inhibitor,
was determined to be 1 µM for Prg4 expression using a serial dilution approach (Figure
2.12a). We similarly tested the effects of AS 1842856, a FOXO1-selective inhibitor, on
the induction of Prg4 expression by TGF-β stimulation in P1 chondrocytes (Figure
2.12b). However, FOXO1 inhibition with AS 1842856 did not inhibit Prg4 induction
until 10 µM, the highest dose tested, and this was likely a non-selective effect due to
toxicity, as determined by phase contrast microscopy (Figure 2.12c).
To explore the extent of TGF-β signaling in the mechanism of Prg4 induction in primary
articular chondrocytes in co-cultures by co-culture with 4W PTOA synovium, we
stimulated naïve confluent P1 articular chondrocytes cultures with stored conditioned
media from the same co-culture experiments that had previously demonstrated Prg4
induction by 4W PTOA synovium and their age-matched sham and naïve synovium
controls. Chondrocytes treated with conditioned medium from 4W PTOA, sham, and
naïve synovium all increased Prg4 expression compared to chondrocytes in nonconditioned serum-free medium (Figure 2.13). However, unlike the original co-cultures,
conditioned medium from 4W PTOA synovium co-cultures did not significantly increase
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Figure 2.12. P1 articular chondrocytes incubated with inhibitors of TGFBR1 and
FOXO1.
Confluent P1 articular chondrocytes were cultured in serum-free medium for 24 hours
with DMSO only, 10 ng/mL TGF-β + DMSO, and 10 ng/mL TGF-β + various
concentrations of a) TGFBR1 inhibitor SB 431542 or b) FOXO1 inhibitor AS 1842856.
qPCR analysis of Prg4 expression levels is displayed as ΔCq relative to reference gene
Rpl13a (mean ± 95% CI, n = 4, *p < 0.05). c) Representative phase-contrast micrographs
of chondrocytes in serum-free culture with DMSO control, 1 µM SB 431542, or 10 µM
AS 1842856 (n = 4). Bar represents 100 µm.
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Figure 2.13. Prg4 expression levels in P1 articular chondrocytes incubated with
conditioned medium and TGFBR1 inhibitor.
Confluent P1 articular chondrocytes were incubated with serum-free medium and vehicle
(DMSO only), conditioned medium from 4W PTOA, sham, and naïve synoviumchondrocyte co-cultures and vehicle, or with conditioned medium and 1 µM SB 4315421.
qPCR analysis of Prg4 expression levels is displayed as ΔCq relative to reference gene
Rpl13a (mean ± 95% CI, n = 5, *p < 0.05).
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Prg4 expression further compared to conditioned medium from sham and naïve
synovium controls. Treatment with 1 µM TGFBR1 inhibitor significantly reduced Prg4
levels in chondrocytes given conditioned medium from naïve and sham synovium cocultures compared to DMSO vehicle (inhibitor control). Interestingly, chondrocytes
treated with conditioned medium from PTOA synovium co-cultures appeared to decrease
Prg4 expression in response to TGFBR1 inhibitor co-treatment but were not significantly
different. Overall, these results show that Prg4 induction in chondrocytes by co-culture
with synovium, regardless of synovium condition, is only partially mediated by TGF-β
signaling.
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2.5 Discussion
The role of synovium in knee OA is not completely understood, although synovitis is
strongly correlated with worse OA symptoms and disease progression. We set out to
investigate the effects of synovium from early stage PTOA joints on chondrocytes using
a novel in vitro co-culture system and to explore whether physiologic changes occur in
synovium with progression to later stages of OA development.
We first sought to establish a co-culture system that would allow us to study signalling
between synovium and cartilage ex vivo without direct contact. A two-chambered
transwell insert system with small membrane pore size was selected for this purpose. The
biological components consisted of articular chondrocytes that recapitulated the expected
physiological phenotype and whole synovial tissue that reconstituted the threedimensional, population-diverse context of knee synovium.
In developing the chondrocyte component, we determined that sub-confluent young adult
rat primary articular chondrocytes did not adequately secrete sGAGs into medium, and
that even confluent chondrocyte cultures showed high variation between replicates with
one donor per replicate. Since Sprague-Dawley rats are outbred, variation in cartilage
homeostasis between individuals likely explains the observed inter-individual variability
in chondrocyte sGAG secretion and gene expression. This variability was effectively
reduced when we adjusted our chondrocyte model by expanding a pool of naïve
chondrocytes from a single animal to allow for many co-cultures to be run with the same
biological baseline. We also confirmed reports from the literature that passaging primary
chondrocytes from P0 to P1 did not cause significant loss of chondrocyte phenotype, as
shown by sGAG release and stable expression of key genes related to chondrocyte
function (Acan, Col2a1, Prg4) and phenotypic transcriptional regulators (Runx2,
Sox9)57,58,59. Future larger scale experiments could extend these results using cells from
multiple animals pooled together and expanded to make stocks of a mixed-source adult
primary articular chondrocyte “cell line”. This has significant advantages over
transformed cell lines that are chondrogenic but do not behave exclusively similar to
articular chondrocytes. Although selective pressures may present a degree of bias in P1
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chondrocytes, such effects are likely minimized by the single passage. Our approach also
allowed us to demonstrate the utility of this model to directly investigate the physiology
of adult rat primary articular chondrocytes, which has not previously been well
established in the literature.
In developing the synovium component of our co-culture system, we found that
dissociated synovial cells were slow to grow and had less potential to impact chondrocyte
physiology when placed into co-culture, with inadvertent selection for more readily
expanding synovial fibroblasts. Thus, we elected to use intact synovial tissue, with all
dissected tissue from a single donor knee per co-culture replicate. Synovial tissue
samples showed no significant signs of apoptosis or necrosis throughout the tissue. We
pre-conditioned serum-free medium with isolated synovial tissue for 24 hours after
collection to allow for conditioning of the medium prior to transfer into co-culture. Since
our preliminary experiments demonstrated that chondrocyte gene expression changes
peak between 12 and 48 hours after reception into our co-culture system, we chose 24
hours in our final co-culture model. We adjusted our system to study healthy articular
chondrocyte responses to synovium from early and later PTOA knee joints. However,
this system could also be used to study other joint diseases where rat models are
available, such as rheumatoid arthritis60. For our studies, two control conditions were
used. Synovium from surgically-naïve joints controlled for animal age, strain, and
housing conditions. Synovium from sham surgery joints additionally controlled for
surgical effects including procedural stress, drugs given, arthrotomy, hemoarthrosis, and
wound healing. Although sham surgery controls are typically the only control used in
most surgical PTOA studies, naïve controls allowed us to differentiate which chondrocyte
responses were specific to PTOA from effects due to surgical trauma to the synovium.
In the 4W PTOA co-cultures, Col2a1, Il6, and Il17a expression in chondrocytes cocultured with either sham or PTOA synovium were significantly different from naïve but
not from each other, suggesting these changes are due to synovial injury and healing from
the surgical procedure, rather than early PTOA. Conversely, Mmp3 and Prg4 expression
and sGAG release increased in chondrocytes co-cultured with PTOA synovium compared
to naïve controls, with sham values trending upward but not significantly, suggesting that
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synovial injury and PTOA work together to induce a protective effect. Previous studies of
early PTOA cartilage gene expression found that Mmp3 was upregulated due to increased
pro-inflammatory factors such as IL-1β and TNF-α, while Prg4 has been shown to be
downregulated61,62,63,64,65. In contrast, our studies demonstrate that early PTOA induces
Prg4 expression. Although PRG4 is widely regarded to have protective effects on joint
health, decreased levels of PRG4 in synovial fluid and downregulation of Prg4
expression in chondrocytes is one of the earliest responses to joint injury and thought to
increase the risk of progression to PTOA in patients after traumatic rupture of the anterior
cruciate ligament66. Therefore, our results point to a possible protective role of synovium
in early PTOA development.
Further supporting a potential protective role of early PTOA synovium, synovial injury in
the sham synovium control downregulated chondrocyte Acan expression at both 24 and
120 hours of co-culture, while PTOA synovium was protective and rescued this effect by
restoring Acan expression to levels similar to that of the naïve controls. We would not
have been able to detect this effect without both naïve and sham surgery controls.
Aggrecan breakdown is a critical event in the pathogenesis of early OA, but the evidence
describing the direction of Acan regulation in early OA is mixed67,68. The increase in
sGAG secretion, which suggests that chondrocytes increase sGAG synthesis when cocultured with early PTOA synovium, also contributes to an anabolic effect. Past studies
have often conflated proteoglycan content and glycosaminoglycan content in assessing
cartilage conditions such as fixed charge density and sulfate metabolism with the
reasoning that the two are biochemically and functionally coupled, but their production
and composition may not be so in OA. Experimental animals models have found OA
cartilage sGAG levels are decreased or not significantly different from healthy controls,
but a study of cartilage post-traumatic knee injury in human patients has found increased
sGAG levels69,70,71,72. Considering the induction of Mmp3, Prg4, and Acan expression
and increased sGAG release in our co-culture system, the effects of early PTOA
synovium indicate overall that a regenerative response may be induced in articular
chondrocytes. This overall protective effect does not support our original hypothesis that
early PTOA synovium would induce pro-inflammatory and catabolic changes in
chondrocytes. In contrast, it stands to reason physiologically that an early, endogenous
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repair response in the pathogenesis of PTOA might be mediated in part by signaling
between the synovium and articular cartilage.
As we identified an overall protective effect of early PTOA synovium on articular
chondrocytes, we next contrasted these effects by co-culturing chondrocytes with
synovium from a later stage of PTOA to determine if the synovium physiology evolves as
experimental PTOA progresses. Our results indicate that the protective effect of early
PTOA synovium on chondrocyte physiology is almost completely lost by 12 weeks after
PTOA induction. At this timepoint, our hypothesis was refuted, with only a decrease in
Ccl2 expression induced by PTOA and sham synovium compared to age-matched naïve,
which may indicate a less inflammatory state induced by surgery. In our PTOA model at
12 weeks, there is significant progression of joint damage as measured by
histopathological scoring. Previous studies using various other rat PTOA models have
noted early histological changes, including lining layer proliferation, inflammatory
infiltrate, and angiogenesis which progress with later disease, with lining layers further
increasing, more dense subsynovial infiltrate, and dilation of blood
vessels73,74,75,76,77,78,79,80. Although some features may progress with later stages of OA, it
is difficult to identify stage-specific changes in OA synovium with histology alone.
Moreover, little information is reported about the physiology of OA synovium, let alone
with respect to disease stage. Studies on synovitis in human patients have compared
synovial cell populations in early and late PTOA and found increases in mainly
macrophages and T cells, while one recent study in a murine PTOA model showed
temporal patterns of macrophage recruitment, activation, and polarization in the
synovium following experimental surgery, albeit with no differences between PTOA and
sham surgery control81,82,83. These results suggest that after injury, a transition in synovial
physiology occurs with progression of PTOA, perhaps toward a less regenerative state. In
our experiments, both the significant increase in chondrocyte Il6 expression and the
decrease in Il17a with injured synovium from both sham and PTOA joints were
maintained through 12 weeks post-surgery. As both cytokines have pro-inflammatory
functions which synergize with other inflammatory signals and are increased in human
OA joints, this outcome is another mixed effect indicative of a complex response17,18,84,85.
This may have implications for treating PTOA in patients, as early inflammatory
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responses after joint injury may in fact be necessary to trigger tissue healing. Treatments
for PTOA, as well as other forms of OA, may need to be tailored for early versus later
stages of disease development.
The mechanisms resulting in Prg4 (encoding lubricin) induction in chondrocytes cocultured with early PTOA synovium remains unclear from our studies, but is most likely
an overall net result of multiple contributing pathways. TGF-β has been shown to
stimulate increased lubricin production in primary articular chondrocyte cultures53,55.
Treatment with TGFBR1 inhibitor significantly but only partially reduced the
upregulation of Prg4 by conditioned medium from co-cultures compared to serum-free
medium, indicating that TGF-β signaling is at least partially responsible for Prg4
induction in chondrocytes in a healthy joint context. Although FOXO1 may regulate
Prg4 in addition to synergizing with TGF-β, we were not able to inhibit FOXO1 without
toxic effects56. Interestingly, although chondrocytes expressed higher Prg4 levels in coculture with 4W PTOA synovium compared to naïve synovium, conditioned medium
transfer from the co-cultures onto fresh chondrocytes did not significantly increase their
Prg4 levels compared to conditioned medium from naïve synovium co-cultures, contrary
to our expectations. This suggests that cross-talk between PTOA synovium and
chondrocytes may be required to further induce Prg4 expression in a PTOA context
specifically. Alternatively, unstable signaling mediators may have been lost over time in
storage, and further experiments transferring conditioned medium directly may reproduce
the difference in Prg4. Although we did not measure the impact of TGFBR1 inhibition
on Acan and Col2a1 expression, TGF-β has been linked to both in chondrocyte
homeostasis and future experiments will include these genes86. Other signaling pathways
with investigative potential include ERG (erythroblast transformation-specific related
gene), which regulates lubricin in the murine joint and has been found to be upregulated
in human OA lesions, and members of the nuclear factor of activated T cells (NFAT)
family, where loss of Nfatc1 and Nfatc2 decreased Prg4 levels in mice, and NFATc4 has
been linked to TGF-β signaling87,88,89,90.
Our study has several limitations. Ex vivo conditions have the potential to influence cell
responses, and the process of dissecting and isolating synovial tissue and primary
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chondrocytes could be affecting results. However, results from our final experiment with
conditioned medium transfers show different results in a static culture system vs a live
co-culture system. This observation suggests that the presence of live synovial tissue in
our co-culture system is required for maximal effects and produces interactivity between
the in vitro biological models of synovium and cartilage. Although changes in gene
expression do not necessarily translate to changes in protein expression and thus longterm physiology, our co-culture system is capable of demonstrating and testing
interactivity between synovium and cartilage to model similar interactions at the joint
level in vivo. Passage from P0 to P1 and subsequent expansion may alter primary
chondrocyte phenotype and select proliferative clones. Furthermore, although we
assessed the effects in healthy chondrocytes, we did not examine the responses of OA
chondrocytes in co-culture with PTOA synovium, which could differ. However, OA
chondrocytes are often more senescent, and we would need to confirm that loss of the OA
phenotype does not occur with passage. The rat PTOA model endpoints selected at 4W
and 12W post-surgery are based on previous PTOA rat models in the literature, but may
not represent the full spectrum of OA pathophysiology or changes that occur earlier or
later in disease development. Finally, the pathogenesis of PTOA in rat knee synovium
may not reflect human PTOA, or other forms of OA, and thus the protective effect of
early PTOA synovium should be confirmed in human joint tissues.
In summary, we have established a responsive co-culture model for investigating the
interaction between synovial tissue and articular chondrocyte interaction in rats.
Furthermore, this system demonstrated adequate sensitivity to identify disease-specific
responses using a rat model of experimental PTOA, which could be adapted further to
study other joint diseases where rat models are available. Our PTOA studies demonstrate
a surprising but logical protective effect induced by PTOA joint synovium on healthy
chondrocytes through mechanisms which are at most only partially dependent on TGF-β
signaling. Understanding the mechanism of why synovium loses this effect with disease
progression is a critical observation for studies of OA pathophysiology and may provide
additional therapeutic insights into the importance of appropriate timing for different
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interventions for OA. Enhancement and support of synovial signals, rather than
suppression, may prove beneficial, at least in early PTOA.
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Chapter 3
Targeting synovial macrophage activation affects chondrocyte
and joint outcomes in experimental post-traumatic
osteoarthritis.
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3.1 Chapter Summary
Osteoarthritis (OA) is the most common joint disease and causes major societal and
personal burdens. No disease-modifying drugs have been approved despite extensive
cartilage research. Although inflammatory processes in cartilage and synovium are
suspected to play a role, the functional impact of synovial macrophages in signalling
between synovium and cartilage in OA is not well understood. This study investigated
potential roles of synovial macrophages in experimental OA development. Synovial
macrophages were selectively manipulated in vivo with intraarticular injections of drugladen liposomes to induce depletion, STAT1 inhibition, or STAT6 inhibition in a rat
model of post-traumatic knee OA (PTOA). As we previously determined the effects of
PTOA synovium on chondrocytes using our ex vivo co-culture model, we also explored
roles played by macrophages in controlling chondrocyte responses to PTOA synovium in
vitro.
PTOA was surgically induced in young adult rat knees, followed by intraarticular
injection of liposomal clodronate (macrophage depletion), fludarabine (STAT1 inhibitor),
AS 1517499 (STAT6 inhibitor), or PBS (control), at 14 and 21 days post-surgery. Painrelated behavior was measured at baseline (pre-surgery) and 4 weeks post-surgery prior
to histopathological assessment of synovium and cartilage. Synovium was collected from
additional animals for co-culture with healthy adult articular chondrocytes. Co-cultures
were evaluated for sulfated glycosaminoglycan (sGAG) secretion into medium and
chondrocyte gene expression.
In 4 week PTOA joints, depletion of synovial macrophages decreased synovitis scores for
lining proliferation, subsynovial infiltration, and fibrin deposition in joints compared to
control. Inhibition of STAT1 in synovial macrophages significantly decreased
subsynovial infiltration scores. Inhibition of STAT6 decreased scores for lining
proliferation, infiltration, and fibrin, similar to macrophage depletion. No changes were
found for any treatment in cartilage damage scores or pain-related behavior. In cocultures, synovium from macrophage-depleted 4 week PTOA joints induced significant
downregulation of Col2a1 expression in chondrocytes. Synovium from STAT1 inhibitor-
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treated joints induced significantly increased sGAG secretion and Acan, Adamts5, and
Mmp13 expression. Synovium from STAT6 inhibitor-treated joints induced upregulation
of Acan and Ccl2 and downregulation of Col2a1.
In conclusion, all three liposomal drug treatments for synovial macrophages impacted
synovial appearance, and each drug had a different pattern of effects. Signalling from
synovium on cartilage is impacted by drug treatment, suggesting that future experiments
with joints at a later stage of OA may show greater effects on cartilage damage and painrelated behavior.
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3.2 Introduction
Osteoarthritis (OA) is the most prevalent joint disease and an increasingly greater health
problem. Commonly occurring in the joints of the knee, hip, hand, and shoulder, OA
results from pathological changes in articular cartilage, subchondral bone, synovium, and
other joint tissues1. Patients experience varied pain and loss of mobility resulting in
disability. OA is a multifactorial disease, and major components include age, sex,
obesity, genetics, previous injury, and joint morphology2. The economic and social
burden of OA is considerable; in 2010, hip and knee OA were ranked as the 11th highest
out of 291 disease categories in disability-adjusted life years lost globally3. Current
treatments focus on symptom management, as no disease-modifying drugs have been
approved for patient use4. Novel strategies for treating OA that reduce damage to
cartilage and other joint tissues in addition to reducing symptoms are urgently needed.
OA has been discussed as a chronic wound of the synovial joint5. Although the exact
cause of OA is unknown, current understanding is that catabolic and anabolic processes
in chondrocytes become unbalanced, with increasing production of catabolic and proinflammatory factors resulting in the destruction and eventual complete loss of articular
cartilage, with pain and loss of function of the joint1. The role of the synovium in OA
pathogenesis is not well understood, but synovitis is present as heterogenous low-grade
(relative to other forms of inflammatory arthritis) inflammation in a large proportion of
patients with knee OA6. Synovitis is correlated with disease progression and greater pain,
and knee synovitis is predictive of OA incidence7,8. Microscopic examination of OAassociated synovitis shows increased proliferation of the intima, mononuclear cell
infiltration, and increased vascularity9.
Macrophages (Mϕ) play central roles in maintaining tissue health through proinflammatory signaling, anti-inflammatory signaling, apoptotic cell clearance, and matrix
growth and remodeling10. Synovial macrophages monitor the joint environment and
modulate other cells in the joint (Figure 3.1)11. They affect the production of various
growth factors, including TGF-β, vascular endothelial growth factor, and nerve growth
factor12,13. Additionally, a subset of synovial macrophages are known to form an
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epithelium-like barrier in the joint lining with tight junctions, which is disrupted in
rheumatoid arthritis 14. In early OA synovium, macrophages from the periphery infiltrate
the tissue in significantly greater numbers15. Macrophage phenotype is plastic; when
activated by different signals, macrophages dynamically polarize into functional
subsets16. The classical spectrum describes these subsets as pro-inflammatory (“M1like”), tending to produce catabolic factors such as TNF-α, and anti-inflammatory (“M2like”), tending to produce anabolic factors such as TGF-β, although polarization is
functionally complex with overlapping characteristics17. These phenotypes are chiefly
driven by the activity of transcription factors signal STAT1 and NF-κB for M1-like and
STAT3 and STAT6 for M2-like, with crosstalk between pathways16,18. STAT activity in
synoviocytes has been implicated in the inflammatory pathways of rheumatoid arthritis,
but less is known in the OA context19. Recent studies have found that negative regulation
of cytokine-activated janus kinase/STAT signalling is reduced in human OA
chondrocytes, contributing to cell death, but the implications for synovium are unclear20.
Our previous work using a rat model of experimental post-traumatic OA (PTOA) has
shown that this model develops synovitis and that co-culture of early PTOA synovium
induces protective physiologic responses in healthy chondrocytes (Chapter 2). However,
synovium from later stage PTOA did not induce these effects, suggesting plasticity of
synovial physiology over time as PTOA develops and progresses. Synovial macrophages
are a significant effector cell population and play important roles in the joint. Therefore,
shifting of macrophage function induced by OA evolution may also be responsible for the
less of the protective effect at a later stage of PTOA.
Previously, synovial macrophages have been found to significantly drive inflammatory
cytokine and matrix protease production by synovial fibroblasts in human OA synovium
and osteophyte formation in murine PTOA21,22,23. Systemic depletion of macrophages in
a murine post-traumatic and metabolic OA model did not affect OA development but
resulted in greater knee inflammation24. Although our results support a hypothesis that
the synovium provides an initially protective effect in chondrocytes in early PTOA,
whether macrophages are required or involved in this effect is unknown.

73

Figure 3.1. Signalling mediators and cells involved in OA synovitis.
Diagram of the OA joint with labels indicating signaling mediators and cell types
involved in low-grade inflammation of the synovium. Image reproduced from Sellam &
Berenbaum 201011.
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In this study, we adapt a strategy to deplete macrophages with clodronate liposomes and
report a novel strategy for shifting synovial macrophage physiology with selective STAT
inhibitor liposomes. Phagocytes recognize large liposomal particles (>0.5 μm) as foreign
and engulf them to form phagosomes, triggering breakdown of the particle in
phagolysosomes and release of the contents into the cell25. Intrarticular injection of drugladen liposomes therefore selectively deliver drug to synovial macrophages, which form
the vast majority of phagocytes in the synovial joint lining. We then explored the effects
of manipulating macrophage activation in early PTOA synovium on disease development
in vivo and on articular chondrocyte physiology in vitro.

75

3.3 Materials and Methods
Reagents
Chemical reagents and histology supplies were purchased from Fisher Scientific or
MilliporeSigma unless otherwise specified. Cell and tissue culture media were purchased
from Gibco, while tissue culture plastics were from BD Falcon. RNA isolation reagents
were purchased from Invitrogen. PCR reagents and equipment, including analysis
software, were all supplied by Bio-Rad.

Liposome source and manufacture
Commercial PBS-only liposomes (vehicle-lip) and clodronate liposomes (clod-lip) were
purchased from Encapsula Nanosciences. These commercial preparations contained 18.8
mg/mL L-α-phosphatidylcholine and 4.2mg/mL cholesterol in PBS as 1.5-2 µm
liposomes, with 18.4 mM clodronate solution encapsulated in clod-lip. To make
fludarabine liposomes (STAT1i-lip), a spontaneously formed vesicle dispersion was
prepared by rotary evaporation of L-α-phosphatidylcholine and cholesterol mixed to
match the commercial preparations (7:3 molar ratio) in chloroform at 30 rev/min and 420
mbar in a 55C water bath, removing remaining traces of chloroform under high vacuum
for 24 hours, and hydrating the phospholipid film formed with 2.5 mg/mL fludarabine
phosphate in PBS. The vesicle dispersion was then extruded six times through 1.0 µm
pore polypropylene filters to form a liposome suspension. To make AS 1517499
liposomes (STAT6i-lip), L-α-phosphatidylcholine, cholesterol, and 1 mg/mL AS
1517499 were mixed in chloroform, evaporated, hydrated in PBS, and extruded as above.
Initial batches of liposomes were checked for shape and structure by fixation in 1.5%
paraformaldehyde and 1.5% glutaraldehyde in PBS and processing for imaging on a
Philips Electronics CM10 Transmission Microscope with a with a Hamamatsu ORCA
2MPx HRL Camera (Figure 3.2a). Size distribution in all batches was checked by
dynamic light scattering on a Zetasizer Nano ZS (Malvern Panalytical) to match that of
the commercial preparation (Figure 3.2b).
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Figure 3.2. Morphology and size distribution of manufactured drug-laden
liposomes.
a) Representative transmission electromicrograph of liposomes made by extrusion. Bar
represents 200 nm. b) Sample size distributions of two lots of drug liposomes compared
to the commercial vehicle liposome preparation.
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Experimental PTOA rat model
All experiments were performed according to the Animal Use Protocol approved by the
institutional Animal Care Committee (Appendix A). Outbred Sprague-Dawley rats (strain
code 400) were sourced from Charles River Canada and fed a standard chow diet ad
libitum. Following a previously established protocol, surgery was performed on the right
knees of 12-week-old male rats26,27. Female rats were not included in this study. Briefly,
animals were given prophylactic ampicillin and buprenorphine for post-procedure
analgesia subcutaneously. Anesthesia was induced with isoflurane gas. PTOA was
induced by incising the medial aspect of the anterior joint capsule to open the right knee
joint, transecting the anterior cruciate ligament and the medial meniscotibial ligament at
its attachment to the meniscus, and closing the joint capsule with absorbable sutures.
Animals received a 50 µL intraarticular injection of liposomes in the operated knee on
day 14 post-surgery and a second 50 µL injection on day 21. Injections were delivered
using a Hamilton syringe through a 30-gauge needle through the patellar tendon to
minimize trauma. The primary endpoint for all analyses was 4 weeks post PTOA
induction.

Tissue histology and histopathological scoring
Knee joints were fixed overnight at 120° flexion and decalcified with Decal Stat (StatLab
for 24 hours, followed by coronal hemisection into anterior (containing infrapatellar fat
pad and para-articular tibial bone only) and posterior portions, then further decalcified
with Formical-2000 until sufficient tissue pliability was reached (approximately 7 days),
and processed for paraffin embedding overnight. Tissues were sectioned in the frontal
plane to ensure all four tibiofemoral cartilage articulations were visible, at 5 µm per
section with 5° blade bevel angle. Twenty adjacent sections were collected every 600 µm
through the joint.
Two adjacent sections every 600 µm were stained with Toluidine blue to score articular
cartilage damage (OARSI scale, cartilage degeneration component only28); briefly, four
articular facets visible in the frontal section (medial and lateral femoral condyle and tibial
plateau) were split into inner, middle, and outer thirds, with each third graded 0-5 (0 = no
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damage, 1 = minimal damage, 5-10% of cartilage area affected by chondrocyte or matrix
loss, 2 = mild, 11-25% affected, 3 = moderate, 26-50% affected, 4 = marked, 51-75%
affected, 5 = severe, >75% affected) for a total score out of 15 per articular facet. Two
adjacent sections every 600 µm were stained with Harris modified hematoxylin and eosin
to assess synovitis (six-component score29); briefly, six compartments visible in the
frontal section (medial and lateral parapatellar, superior, and inferior) were scored 0-3 (0
= normal, 1 = mild, 2 = moderate, 3 = severe) for a total score out of 18 in each of six
categories (synovial lining thickness, synovial infiltration, fibrin deposition,
vascularisation, fibrosis, perivascular edema). Slides were imaged on an Olympus BX53
microscope with an Olympus DP73 camera.
Immunohistochemistry was performed on adjacent sections for CD68+ cells as an
indicator of macrophage presence. Slides underwent antigen retrieval by immersion in 10
mM Tris, 1 mM EDTA, 10% glycerol buffer at pH 9.0 heated to 70C and gradually
cooled to room temperature. Slides were then immersed in 0.2% Triton X-100 in PBS for
10 min to permeabilize cells, followed by 3% hydrogen peroxide in PBS for 15 min to
block endogenous peroxidases. Sections were blocked with 1% bovine serum albumin
(GE Healthcare), 0.1% Triton X-100 in PBS for one hours. One section on each slide was
kept in blocking buffer as a control for nonspecific binding, while the adjacent section
was probed with rabbit anti-rat CD68 primary antibody (Abcam ab125212) diluted 1:100
in blocking buffer at 4C overnight. Both sections were probed with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody diluted 1:4000 in PBS at room
temperature for 1 hr. Colorimetric detection was performed on slides using the DAB
Peroxidase Substrate Kit (Vector Laboratories) following manufacturer instructions.
Slides were counterstained with hematoxylin before mounting and imaged as above.

Pain-related animal behavior measurements
Mechanical allodynia and hyperalgesia measures were taken at baseline pre-PTOA
induction and 4 weeks post-PTOA induction. The increased sensation of pain in response
to non-noxious (allodynia) and noxious (hyperalgesia) stimuli is a feature of OA which is
replicated in rat models30,31,32,33.

79

Allodynia was measured using the Electronic Von Frey (EVF) unit (Bioseb). Animals
were placed in an elevated bar-bottom platform to equilibrate for twenty minutes prior to
testing to minimize ambulation. Readings were taken by pressing the tip of the EVF
sensor to the plantar surface of the right hind paw at approximately 25 grams/second until
paw withdrawal by the animal, with fifteen minutes between repeated measures. The
average of two acceptable readings was recorded as the final threshold value.
Hyperalgesia was assessed by pressure application measurement using the Small Animal
Algometer (SMALGO) unit (Bioseb). Animals were manually restrained with the right
hind leg exposed. Readings were taken by attaching the SMALGO pressure sensor to the
experimenter’s thumb and pinching the knee with the sensor on the medial side at
approximately 200 g/sec. A single threshold value was taken at the point where the
animal attempted to withdraw the limb or vocalized discomfort.

Joint tissue cultures and co-culture system
Knee joint tissues were collected by gross dissection. Overlying skin, muscle, and tendon
were removed from legs before opening the joint under sterile conditions. Primary
articular chondrocytes were collected from two healthy, surgically-naïve 16-week-old
male rats. Femoral and tibial articular surfaces were shaved using a scalpel and carefully
excluding contamination by periosteum, meniscus, or bone. Cartilage from four joints
were pooled together and minced into pieces of approximately 1 mm3 in DMEM with
10% fetal bovine serum (FBS), 1% Antibiotic-Antimycotic, 800 U/mL collagenase II,
and 100 U/mL DNase I, and run for 2 hours at 37C with variable agitation on a Miltenyi
Biotec gentleMACS Dissociator. The resulting suspension was triturated, passed through
a 70 µm cell strainer and washed with primary chondrocyte medium (1:1 DMEM/Ham’s
F12, low glucose, L-glutamine, with 10% FBS and 1% penicillin-streptomycin). Live
cells were counted on a Bio-Rad TC20. Primary chondrocytes were seeded at 2-5% in
T75 flasks in primary chondrocyte medium, with medium changes every 2-3 days until
confluent. Expanded P0 chondrocytes were trypsinized, gradually frozen to -80C in FBS
with 10% DMSO, and stored in liquid nitrogen.
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Knee joint synovium was dissected over serum-free 1:1 DMEM/F12 with 1% penicillinstreptomycin with care to keep the tissue intact. After opening the joint by cutting around
the suprapatellar region, the menisci and patella were removed, and synovium was peeled
away from the outer fibrous capsule. All synovium from a single joint was placed into a
seated 12-well transwell inserts, 0.4 µm pore size, with serum-free medium in both
chambers.
For co-cultures, P1 articular chondrocytes were thawed from frozen stocks, washed with
primary chondrocyte medium, seeded at 10% density into 12-well plates, and expanded
until confluent. Prior to the start of the culture period, chondrocytes were serum-starved
overnight (8 to 16 hours) and synovial tissue was placed into serum-free medium for 24
hours to equilibrate. Co-cultures were assembled by transferring the synoviumconditioned medium from the lower chamber onto the serum-starved chondrocytes and
placing the transwell insert with synovium and conditioned medium on top.

Dimethylmethylene blue (DMMB) assay
Conditioned medium from co-cultures was assayed for sulfated glycosaminoglycan
(sGAG) content using a protocol based on previously described methods34,35. In
microwell plates, 200 µL DMMB reagent (38.46 mmol 1,9-dimethyl-methylene blue zinc
chloride, 40.5 mmol glycine, 27.38 mmol sodium chloride, 9.5mmol acetic acid
(Bioshop)) was combined with 100 µL of conditioned medium or chondroitin sulfate
standards diluted to the appropriate range in serum-free chondrocyte medium in triplicate
and read immediately at absorbance wavelength 595 nm with reference wavelength 655
nm on a Safire plate reader (Tecan Life Sciences).

RNA isolation and gene expression analysis
We made efforts to adhere to the minimum information for publication of quantitative
real-time PCR experiments (MIQE) guidelines where possible regarding controls for
contamination and technical error36.
Co-cultured chondrocytes were lysed by adding TRIzol to each well and triturating.
Samples were transferred to phase separation tubes, combined 5:1 with chloroform,
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shaken for 50 seconds, and centrifuged at 12,000 x g for 15 minutes at 4C. The RNEasy
Mini Kit (QIAGEN) was used for co-cultured chondrocytes and the Direct-zol RNA
Miniprep Kit (Zymo Research) was used for peripheral blood monocyte-derived
macrophages. Kit instructions were followed for subsequent steps, including combining
the aqueous phase was combined with an equal volume of 70% ethanol and transferred
onto silica spin columns, followed by on-column DNase I digestion, washes, and elution
into nuclease-free water. Eluted RNA yield and purity was measured on a Nanodrop 2000
(Thermo Scientific). Samples were reverse transcribed using iScript Reverse
Transcription Supermix following manufacturer thermal cycle recommendations.
Quantitative real-time PCR (qPCR) was performed by combining SsoAdvanced
Universal SYBR Green Supermix, predesigned primers (Table 3.1), and cDNA template
in triplicate. Template per reaction varied by gene. Plates were thermocycled as follows:
an initial polymerase inhibitor removal step at 95C for 30 s, a repeating denaturation step
at 95C for 15 s followed by an annealing and elongation step at 60C for 30 s for 40
cycles, with an ending melt-curve analysis from 65C to 95C in 0.5 C steps at 2 s/step. Cq
values were calculated on CFXMaestro 1.1 and normalized to reference genes Hprt1 and
Pop4 for macrophages and Rpl13a and Rplp0 for chondrocytes. Reference genes were
selected prior to target gene assessment using the Bio-Rad pre-designed rat reference
gene panel with representative samples and CFXMaestro Reference Gene Selector tool.

Primary peripheral blood-derived macrophage cultures
Rat peripheral blood monocytes were isolated at euthanasia. Following SepMate
manufacturer instructions and recommended volumes, whole blood was collected via
cardiac puncture from healthy 16-week-old male rats, combined with an equal volume of
2% FBS in PBS, layered over Ficoll-Paque PREMIUM 1.084 in SepMate tubes, and
centrifuged at 2200 x g for 20 min at room temperature. The top layer containing
monocytes was decanted into a new tube and washed with 2% FBS and RPMI 1640 with
10% FBS and 1% penicillin-streptomycin at 300 x g for 10 minutes. Cells were plated in
macrophage medium (RPMI 1640 with 50 ng/mL recombinant murine M-CSF
(PeproTech), 10% FBS, and 1% penicillin-streptomycin) at 200,000 cells per well in 24-
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Table 3.1. Reference information for Bio-Rad PrimePCR™ PCR primers.
Gene
Acan
Adamts5
Arg1
Ccl2
Col10a1
Col2a1
Hprt1*
Il6
Il17a
Mmp13
Mmp3
Pop4*
Prg4
Rpl13a*
Rplp0*
S100a8
Sox9
Tgfb1
Tnf

Amplicon
Context Sequence
1:141780455-141787109
11:29043239-29056911
1:23010271-23012299
10:69048547-69048678
20:42913429-42916882
7:139647809-139647911
X:153250276-153250384
4:3095863-3097287
9:25698119-25699513
8:5531849-5533218
8:5689395-5691167
1:95761052-95761187
13:72640183-72642005
1:102186223-102186424
12:48589001-48589127
2:209508182-209508274
10:100968094-100968214
1:83747870-83750404
20:6937988-6938129

* denotes a reference gene.

Transcription
intron-spanning
intron-spanning
Intron-spanning
exonic
intron-spanning
exonic
exonic
intron-spanning
exonic
intron-spanning
intron-spanning
exonic
intron-spanning
exonic
exonic
exonic
exonic
intron-spanning
exonic

Amplicon
Length
109
120
68
102
120
73
79
120
106
87
66
106
118
87
97
63
91
109
112
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well plates, resulting in 50-70% macrophage differentiation as estimated under phase
contrast microscopy after four days incubated at 37C and 5% CO2. To assess liposome
effects in vitro, differentiated cells were changed into 0.8 mL fresh macrophage medium
with 5 uL of liposome suspension per well, incubated for 24 h, then stimulated with
recombinant murine interferon-γ (IFN-γ) 100 ng/mL (PeproTech) or recombinant rat
interleukin-4 (IL-4) 10 ng/mL (PeproTech) for 24 h.

Statistics
Statistical tests set type I error threshold at α = 0.05. One-way ANOVA followed by
Dunnett’s multiple comparisons test was used for the effects of liposomal drugs
(comparisons between veh-lip, clod-lip, STAT1i-lip, and STAT6i-lip) on pain-related
behavior, histopathological scores, sGAG secretion, and gene expression. Two-way
ANOVA followed by Dunnett’s multiple comparisons test was used for the effects of
liposomal drugs and activating factor on primary peripheral blood-derived macrophages
(comparisons between veh-lip, STAT1i-lip, and STAT6i-lip with M-CSF only, IFN-γ,
and IL-4).
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3.4 Results
Targeted drug delivery to synovial macrophages alters features of
synovitis in early PTOA joints
Sections from 4W PTOA knees injected with drug-laden liposomes were semiquantitatively scored for the appearance of synovitis in different compartments around
the joint. Overall, scores reflect mild to moderate synovitis across all joint compartments,
as expected in this animal model (Figure 3.3). Clod-lip effectively reduced CD68+
staining from the intimal lining (Figure 3.4). Clod-lip treatment resulted in a significantly
decreased score of the number of intimal lining layers, subintimal inflammatory infiltrate,
and fibrin deposition, but increased vascularization scores (Figure 3.5). STAT1i-lip
decreased subintimal infiltration and increased vascularization scores. Similar to clod-lip,
STAT6i-lip decreased intimal lining layers, subintimal infiltration, and fibrin deposition
scores. Overall, it appeared that inhibiting or depleting macrophages resulted in
decreased subintimal infiltration and no changes in perivascular edema.

Targeted drug delivery to synovial macrophages does not markedly
affect cartilage histopathological scores in early PTOA joints
Sections from the same 4W PTOA knees were semi-quantitatively scored for cartilage
damage to articular surfaces following the cartilage degeneration component of the
OARSI histopathology grading system24. As expected in this rat model of PTOA, PTOA
joints treated with veh-lip control had minimal to mild focal cartilage damage, with more
damage to the medial articular surfaces (Figure 3.6). Liposome-treated joints scored
similarly, with no significant differences found between any treatments and control in
damage scores for any joint compartment, nor for the cumulative joint scores (Figure
3.7).

Targeted drug delivery to synovial macrophages does not induce
changes in pain-related behavior in early PTOA
Pain-related behavior assessments including mechanical knee hyperalgesia and ipsilateral
hindpaw allodynia were performed on rats at baseline and 4W PTOA to compare the
effects of clod-lip and STAT1i-lip treatment. Pain-related behavior data from this rat
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Figure 3.3. Low-grade synovitis present in liposome-treated 4W PTOA joints.
Representative micrographs of H&E stained synovium from 4W PTOA knees injected
intraarticularly with vehicle (veh-lip), clodronate (clod-lip), STAT1 inhibitor (STAT1ilip), and STAT6 inhibitor (STAT6i-lip) treatments (n = 5). Bar represents 100 µm.
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Figure 3.4. CD68+ cells in synovium from clodronate liposome-treated 4W PTOA
joints.
Representative micrographs of synovial lining from 4W PTOA knee joints injected
intraarticularly with vehicle (veh-lip) and clodronate (clod-lip) treatments (n = 5). Brown
stain indicates CD68 with blue hematoxylin counterstain. Arrows indicate CD68+ cells in
intimal lining. Bar represents 100 µm.
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Figure 3.5. Histopathological scoring for features of synovitis in liposome-treated
4W PTOA joints.
Semi-quantitative scoring for features of synovitis in 4W PTOA knee joints injected
intraarticularly with vehicle (veh-lip), clodronate (clod-lip), STAT1 inhibitor (STAT1ilip), and STAT6 inhibitor (STAT6i-lip) treatments (mean ± 95% CI, n = 5, *p < 0.05).
For each histopathological feature, scores indicating 0 = normal, 1 = mild, 2 = moderate,
and 3 = severe were assigned for each of six compartments, totaling a score out of 18 per
compartment; individual scores represent the average of 3-7 slides per joint.
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Figure 3.6. Low-grade cartilage damage present in liposome-treated 4W PTOA
joints.
Representative micrographs of toluidine blue stained medial joint compartments from 4W
PTOA knees injected intraarticularly with vehicle (veh-lip), clodronate (clod-lip), STAT1
inhibitor (STAT1i-lip), and STAT6 inhibitor (STAT6i-lip) treatments (n = 5). Bar
represents 500 µm.
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Figure 3.7. Histopathological scoring for cartilage damage in liposome-treated 4W
PTOA joints.
Semi-quantitative scoring for chondrocyte and matrix loss in 4W PTOA knee joints
injected intraarticularly with vehicle (veh-lip), clodronate (clod-lip), STAT1 inhibitor
(STAT1i-lip), and STAT6 inhibitor (STAT6i-lip) treatments (mean ± 95% CI, n = 5, *p <
0.05). Scores indicating 0 = no damage, 1 = minimal, 2 = mild, 3 = moderate, 4 =
marked, and 5 = severe were assigned for each third of an articular facet, totaling a score
out of 15 per facet and out of 60 per joint; individual scores represent the average of 3-5
slides per joint.
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model of PTOA are not available in the literature. The veh-lip control condition did not
suggest that this model develops mechanical hyperalgesia (Figure 3.8) or allodynia
(Figure 3.9) at the early 4 week time point in PTOA development. No clear trends were
evident for change in limb withdrawal or paw withdrawal thresholds for liposomeinjected animals, with animals becoming both more and less sensitive at 4W PTOA
compared to baseline for both drug liposomes tested.

Targeted drug delivery to synovial macrophages alters articular
chondrocyte physiology
We previously showed that co-culture of whole synovial tissues from early PTOA
induces overall protective responses by articular chondrocytes (Chapter 2). Here, we
explored the role of synovial macrophages in mediating chondrocyte responses when
exposed to synovium using the same co-culture system.
Synovium isolated from 4W PTOA knees injected with drug liposomes differentially
induced changes in adult primary articular chondrocyte sGAG release and gene
expression, compared with vehicle-lip-treated PTOA synovium. Co-culture of articular
chondrocytes with early PTOA synovium from clod-lip-treated (macrophage-depleted)
joints did not significantly alter sGAG secretion (Figure 3.10), but significantly decreased
Col2a1 expression (Figure 3.11). STAT1i-lip-treated early PTOA synovium induced
further sGAG release beyond the sGAG induction induced by early PTOA synovium
alone (Chapter 2). STAT1i-lip also induced significantly increased levels of Acan,
Adamts5, and Mmp13, with strong trends toward increased Col2a1, Mmp3, and Prg4.
Synovium from STAT6i-lip-treated joints caused chondrocytes to trend toward increased
sGAG secretion, but this difference was not statistically significant. STAT6i-lip-treated
synovium induced increased expression of Acan and Ccl2, and decreased expression of
Col2a1 in chondrocytes.

Liposomal drug delivery alters primary peripheral blood-derived
macrophage physiology in vitro
Clod-lip depletion of macrophages is well-established in the literature, but the effects of
liposomal STAT inhibitor treatments are not reported. To determine STAT1i-lip and
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Figure 3.8. Mechanical hyperalgesia in liposome-treated 4W PTOA animals.
Pressure algometry for mechanical hyperalgesia as measured by the SMALGO unit in
PTOA knees injected intraarticularly with (veh-lip), STAT1 inhibitor (STAT1i-lip), and
STAT6 inhibitor (STAT6i-lip) treatments at 4 weeks post PTOA induction (mean ± 95%
CI, n = 10).
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Figure 3.9. Tactile allodynia in liposome-treated 4W PTOA animals.
Pressure algometry for tactile allodynia as measured by the Electronic Von Frey unit in
ipsilateral hindpaws of PTOA knees injected intraarticularly with (veh-lip), STAT1
inhibitor (STAT1i-lip), and STAT6 inhibitor (STAT6i-lip) treatments at 4 weeks post
PTOA induction (mean ± 95% CI, n = 10).
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Figure 3.10. sGAG content in conditioned medium from primary articular
chondrocytes co-cultured with liposome-treated 4W PTOA synovium.
Synovium was collected from 4W PTOA knee joints injected intraarticularly with vehicle
(veh-lip), clodronate (clod-lip), STAT1 inhibitor (STAT1i-lip), and STAT6 inhibitor
(STAT6i-lip) treatments. Synovial tissues were co-cultured with healthy adult primary
articular chondrocytes for 24 hours. Conditioned medium was collected and measured for
sGAG content by DMMB assay (mean ± 95% CI, n = 5, *p < 0.05).

94

✱

8.0
12.0
16.0

4.0
6.0
8.0
10.0

✱

8.0
10.0
12.0

Relative mRNA Expression

Relative mRNA Expression

Prg4

2.0
4.0
6.0
8.0
10.0

4.0
6.0

6.0

2.0

Il6

4.0
6.0
8.0
10.0
12.0

2.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Mmp13
✱

4.0
6.0
8.0
10.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Relative mRNA Expression

2.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

6.0

0.0

8.0

14.0

4.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Mmp3

-2.0

✱

2.0

8.0

Relative mRNA Expression

Relative mRNA Expression

✱

Relative mRNA Expression

Col2a1

4.0

Ccl2

0.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

0.0

✱

12.0

20.0

6.0

Adamts5

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Relative mRNA Expression

Relative mRNA Expression

✱

Relative mRNA Expression

Acan
4.0

Cytokines
& Alarmin

Matrix Proteases
Relative mRNA Expression

Chondrocyte
Genes

15.0

S100a8

16.0
17.0
18.0
19.0
20.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Sox9

7.0
8.0
9.0
10.0

ip
ip
ip
ip
h-l lod-l T1i-l T6i-l
Ve
C STA STA

Figure 3.11. Gene expression in primary articular chondrocytes co-cultured with
liposome-treated 4W PTOA synovium.
Synovium was collected from 4W PTOA knee joints injected intraarticularly with vehicle
(veh-lip), clodronate (clod-lip), STAT1 inhibitor (STAT1i-lip), and STAT6 inhibitor
(STAT6i-lip) treatments. Synovial tissues were co-cultured with healthy adult primary
articular chondrocytes for 24 hours. qPCR analysis of gene expression levels is displayed
as ΔCq (mean ± 95% CI, n = 5, *p < 0.05).
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STAT6i-lip treatment effects on macrophages physiology, primary peripheral bloodderived macrophages were cultured with each type of liposome in medium alone, with
classical activator IFN-γ, or with alternative activator IL-4. STAT6i-lip treatment resulted
in higher Ccl2 expression, while STAT1i-lip did not induce changes in any of the genes
selected (Figure 3.12). Stimulation with IFN-γ, regardless of liposome treatment, induced
macrophages to increase Ccl2 levels compared to unstimulated controls. Ccl2 was
downregulated in macrophages given IL-4 with either liposome treatment, but not back to
the basal level unstimulated level. No significant differences were found between groups
for Tnf. Macrophages incubated with IL-4 significantly upregulated Arg1 with all
liposome treatments, but liposomes did not have an additional effect. Tgfb1 expression
significantly decreased in macrophages treated with IL-4 and STAT1i-lip compared to
IL-4 and veh-lip.
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Figure 3.12. Gene expression in primary peripheral blood-derived macrophages
treated with liposomes and activating factors.
Primary macrophages were differentiated from peripheral blood monocytes with 50
ng/mL M-CSF and incubated for 24 hours with no factor, 100 ng/mL IFN-γ, or 10 ng/mL
IL-4 and treated with vehicle (veh-lip), STAT1 inhibitor (STAT1i-lip), or STAT6
inhibitor (STAT6i-lip). qPCR analysis of gene expression levels is displayed as ΔCq
(mean ± 95% CI, n = 4, *p < 0.05).
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3.5 Discussion
Synovial macrophages are markedly increased in joints from OA patients and
experimental OA models, suggesting that macrophages may play important roles in OA
development or progression15,37. We investigated the effects of synovial macrophage
treatments using drugs to induce depletion or STAT signaling inhibition, targeted to
phagocytes through liposomal encapsulation. We previously discovered that chondrocyte
physiology is altered by co-culture with synovial tissues and that synovium from early
PTOA induces overall protective effects in articular chondrocytes (Chapter 2). To study
the effects of synovial macrophage manipulation on synovium and cartilage in vivo, we
assessed pain-related behavior and histopathological measures of cartilage damage and
synovitis. To study the chondrocyte response to treated synovium, we used our novel coculture model of the synovial joint in combination with macrophage-manipulating
treatments. This included whole joint synovium from 4W PTOA animals treated with
intraarticular liposomal drugs and healthy primary articular chondrocytes cultured in
separate chambers, allowing exchange of signalling molecules.
Our data from clodrosome-injected joints confirmed that these liposomes were effective
at depleting macrophages from the synovial intima and reducing synovitis severity,
consistent with previous reports22,38,39,40. While macrophage depletion reduced
subsynovial infiltration and fibrin deposition, sGAG production did not significantly
differ, suggesting that macrophages are not directly involved in mediating signals from
PTOA synovium to chondrocytes that result in increased sGAG release. However,
macrophage depletion did cause downregulation of Col2a1 expression in chondrocytes,
indicating that macrophages are involved in synovium to chondrocyte signaling.
Although there was no clear effect on histopathological measures of cartilage damage in
the early PTOA, cartilage changes are typically mild at this early stage of experimental
PTOA development. Similarly, no difference in mechanical knee hyperalgesia or
hindpaw allodynia were detected. Interestingly, depletion of macrophages in these
experiments suggest that suppression of Col2a1 expression in chondrocytes by early
PTOA synovium (Chapter 2) may be partially mitigated by synovial macrophages, since
Col2a1 expression was suppressed by PTOA synovium after macrophage depletion.
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Activation of STAT family members through various receptors strongly affects
macrophage polarization. Specifically, STAT1-mediated effects including activation of
NF-κB signaling are known to drive the pro-inflammatory M1-like phenotype, while
STAT3 and STAT6 promote the anti-inflammatory M2-like phenotype16,17. TGF-β,
which induces type II collagen and aggrecan expression in chondrocytes, is found in OA
synovium and known to be secreted by M2-like macrophages,23,41,42,43. This may explain
the partially protective effect of mitigating Col2a1 suppression in chondrocytes exposed
to early STATi-Lip PTOA synovium. Moreover, STAT6i-lip treatment further
suppressed Col2a1 expression. M2-like macrophages in PTOA synovium may be
responsible for producing TGF-β that helps to sustain chondrocyte Col2a1 gene
expression. This would be congruous with the finding that clod-lip suppresses Col2a1
expression, as the loss of synovial macrophages would decrease TGF-β levels in the joint
environment. Further supporting a protective effect of STAT1 inhibition, synovium from
STAT1i-lip-treated joints had decreased subsynovial infiltration and increased
vascularization, and co-cultured chondrocytes upregulated matrix molecules Acan and
Prg4. Increased aggrecan expression may compensate for early cartilage damage, while
lubricin decreases friction in articulation and inhibits chondrocyte catabolism and
hypertrophy44. On the other hand, STATi-lip-treated synovium also upregulated matrix
metalloproteases Adamts5, Mmp3, and Mmp13. Both major synovial cell types are known
to secrete MMPs, and key MMPs are able to cleave the zymogen forms of other family
members in an activation cascade45. With no significant differences found in cartilage
damage and pain-related behavior, it is unclear whether STAT1-lip treatment is
beneficial. Further experiments with longer duration of liposomal drug delivery are
needed to determine overall joint-level effects, through histology and/or protein analyses.
STAT6i-lip treatment was expected to shift synovial macrophages toward the proinflammatory M1-like phenotype. Unexpectedly, STAT6i-lip treated synovium induced
chondrocytes to upregulate Acan in addition to downregulating Col2a1 downregulation in
chondrocytes, suggesting that these matrix components are regulated by different
pathways. Co-cultured chondrocytes also upregulated Ccl2, as did peripheral bloodderived macrophages given STAT6i-lip in vitro. C-C motif chemokine ligand 2 (CCL2),
also known as monocyte chemoattractant protein 1 (MCP1), is increased in OA synovial
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fluid and associated with symptom severity in patients37,46,47. Synovial macrophages and
mesenchymal progenitor cells both express corresponding receptor C-C chemokine
receptor type 2 (CCR2) and produce CCL2, forming the basis for a positive feedback
loop of immune recruitment and inflammation37,48. Chondrocytes can also respond to
CCL2 by producing MMP3 and MMP1349,50. Previous work has found that systemic
administration of a CCR2 inhibitor was protective in experimental PTOA, especially
when given at an early stage51,52. Thus, STAT6 inhibition in synovial macrophages most
likely has a overall pro-inflammatory impact on the joint. Histology of STAT6i-liptreated 4W PTOA joints showed mixed results, with increased vascularization but
decreased intimal lining, subsynovial infiltration, and fibrin deposition in the synovium
and no significant differences in cartilage damage. As with the previous treatment, results
are not conclusive with regard to disease progression. A later PTOA timepoint with
prolonged liposome treatment, such as 12 weeks post-induction, is needed to find
differences not detectable at 4 weeks PTOA.
To characterize changes in synovial macrophages treated with STAT inhibitor liposomes,
peripheral blood-derived macrophage gene expression in vitro was assessed after 24
hours of treatment with liposomes and activating factors. In designing the experiment, we
assumed based on the literature that classical activation with IFN-γ would cause
upregulation of M1-like markers Ccl2 and Tnf and no change or downregulation of M2like markers Arg1 and Tgfb1, while alternative activation with IL-4 would cause the
reverse. Results from these control conditions showed that M(IFN-γ) only upregulated
Ccl2, while M(IL-4) upregulated both Ccl2 and Arg1. In future experiments, different
markers or activating factors should be selected for appropriate phenotyping.
Additionally, fludarabine has been noted to cause downregulation of Stat1 and depletion
of STAT1 lasting multiple days in vitro53. As the pharmacokinetics of liposomeencapsulated drugs differs from that of the free compound, it is unknown whether
STAT1i-lip dosage was high enough to cause significant off-target effects54. We also
predicted that STAT1 inhibition would cause downregulation of Ccl2 and Tnf, in both
M0 and M(IFN-γ), but results showed no significant differences in either. Finally, we
predicted that STAT6 inhibition would cause downregulation of M2-like markers Arg1
and Tgfb1, in both M0 and M(IL-4), but again no significant differences were detected.
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However, as previously discussed, STAT6i-lip did cause significant upregulation of Ccl2,
which may be an indication of shifting toward the M1-like phenotype. Further
characterization of M(STAT1i-lip) and M(STAT6i-lip) phenotype over time is needed,
such as protein analyses for marker expression or microscopy for morphology, given that
drug effects likely must be sustained in vivo to achieve therapeutic effect.
The present study has several limitations. Although fludarabine phosphate and AS
1517499 are selective inhibitors of STAT1 and STAT6, off-target effects cannot be
completely eliminated. As a nucleotide analog, fludarabine inhibits certain proteins
involved in DNA production and can also inhibit RNA production55. Inhibition of DNA
synthesis should not be a major problem in mature tissue macrophages, but they do have
high transcriptional activity, and an overall effect of transcriptional inhibition cannot be
ruled out. AS 1517499 was discovered more recently and its mechanisms of action have
not been extensively examined in the literature. However, for both treatments, no overt
signs of tissue or cellular necrosis such as nuclear condensation and fragmentation were
evident in H&E-stained synovium sections. While our rat model of PTOA has been
previously validated, tissue injury from the intraarticular injections may have additional
effects on the joint environment, although this was controlled for across conditions. We
did not include a no liposome, saline-only control group as a major effect of PBS-only
liposomes on PTOA development is not expected. Local effects of injections may be
avoided through systemic administration, as seen in the reduction of experimental
antigen-induced inflammatory arthritis via systemic administration of clodronate
liposomes, but this approach is unlikely to be successful for other drugs or use in
patients39. Finally, our experiments in investigating physiological differences in
chondrocytes induced by liposome-treated synovium used healthy primary articular
chondrocytes pooled from the joints of healthy young adult male rats and we cannot rule
out the possibility that different responses may occur in OA chondrocytes. As the
liposome-treated 4W PTOA joint environment in vivo includes signals from early PTOA
chondrocytes in addition to the liposomes, use of OA chondrocytes and later PTOA
synovium in future experiments may reveal crosstalk effects beyond the co-cultures used
in this study.
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Our findings conclusively demonstrate that selectively altering synovial macrophage
phenotype via drug-laden liposomes induces physiological changes in the joint, including
the ability to induce important changes in articular chondrocyte gene expression and
synthetic function. Thus, targeting synovial macrophages with liposomal treatments has
the potential impact to impact outcomes in OA. Further experiments are needed to
characterize longer term effects beyond the immediate effects investigated here. Ongoing
work in the lab will address the drug-altered phenotype at later stages of PTOA
development and determine whether the STAT inhibitors used here protect against or
contribute to inflammation and damage as experimental PTOA progresses.
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Chapter 4
Summary and General Discussion
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Figure 4.1. Schematic of research outcomes.
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We set out to investigate the effect of synovium on chondrocytes in knee OA and the role
of synovial macrophages. Cartilage degradation is a major component of OA and a driver
of pro-inflammatory changes in the joint. Synovitis has recently become recognized as
being an important feature, and evidence for synovial macrophages as key effector cells
is building. The work completed here contributes to the body of knowledge on synovium
in a rat model of experimental post-traumatic knee OA.

4.1 Establishment of a synovial joint model ex vivo
Chondrocytes are the sole cell population in cartilage. Unlike chondrocytes in healthy
cartilage, OA chondrocytes actively produce catabolic enzymes and inflammatory
signaling molecules. Many attempted interventions have focused on changing
chondrocyte physiology to restore the balance between anabolic and catabolic processes.
However, such an approach ignores the existence of cartilage as part of a complex joint
environment, where unaddressed chronic inflammation in other tissues such as synovium
likely contributes to the disruption of homeostasis, reducing the effectiveness of
cartilage-selective treatments. Therefore, we focused on measuring chondrocyte gene
expression and sGAG release responses upon exposure to OA synovium. Our intention
was to test the effects of manipulating chronic synovial inflammation on chondrocyte
outcomes in an OA model.
To model the phenotype of adult articular chondrocytes in the joint, we chose to grow
primary articular chondrocytes from healthy knee joints, rather than previously described
cell lines. We also initially chose to use a monolayer culture, rather than bioscaffold or
micromass culture, for ease of use. We used a established rat model of post-traumatic
knee OA, as it reliably induces the onset of OA-like changes in joint tissues in a short
timeframe, and many molecular biology tools are available for rat tissues. However, rats
are small animals, and the number of chondrocytes in a rat knee is limited. Preliminary
experiments initially addressed this limitation by using chondrocytes from a single
experimental joint, and thus animal, for each co-culture replicate. After a high degree of
inter-individual variation was noted in chondrocyte gene expression, we validated the use
of expanded and passaged P1 primary chondrocytes to reduce baseline variation in vitro.
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We focused on gene expression as an early indicator of changes in chondrocyte
physiology over protein expression, which would require further validation. This work
provides the field with a new monolayer culture model using adult rat articular
chondrocytes, which have received less attention relative to human and mouse model
cultures.
To model synovium in the joint, we chose to co-culture whole-joint synovial tissue to
account for the diversity of cells present and minimize the effects of cell isolation for in
vitro culture. No necrosis was detected in tissues after several days in culture, consistent
with previous papers describing extended synovial tissue cultures, but experiments using
longer timelines should validate additional timepoints.
We did not model other joint tissues such as subchondral bone, tendon, ligament, and
articular disc, as their contributions in OA are more likely to be biomechanical than
through signalling. When the components of our co-culture system are put together, the
synovial joint adequately models major signals between synovium and cartilage. The
major strength of our work is the isolation of signaling between these crucial joint tissues,
allowing us to expand our understanding of chondrocyte physiology in context with
synovium, beyond culturing cartilage alone in various forms. Furthermore, the isolation
of synovium-cartilage interactions away from the other tissue-tissue interactions taking
place in the joint environment is another strength, as this would be very difficult to assess
in vivo. Our model is suitable for investigating different experimental OA conditions of
both synovium and cartilage in future work.

4.2 Effects of PTOA synovium condition on chondrocytes
Supporting the observation that this system provides important insights into synoviumcartilage interactions, we showed that even healthy synovium has a very strong effect on
chondrocyte physiology. Compared with chondrocyte gene expression in the absence of
synovium co-culture, we observed marked increases in many chondrocyte genes and
sGAG release. This is a key observation since it demonstrated that studying chondrocytes
in monolayer culture alone may not reflect the nature or magnitude of the responses to
various stimuli that occur in the three-dimensional joint environment.
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Early PTOA synovium induces differences in chondrocyte responses compared to healthy
control. Although changes were found in expression of both anabolic and catabolic genes,
we believe the overall response is protective. Unexpectedly, this response was entirely
absent when chondrocytes were co-cultured with later stage PTOA synovium. The
synovium likely undergoes a phenotypic shift from 4 weeks to 12 weeks post-induction
of PTOA, resulting in the induction of Ccl2, which likely indicates pro-inflammatory
change in gene expression in chondrocytes. Further work is required the understand these
biological changes with gene or protein expression analysis in synovial cell populations.
Although we were able to assess chondrocyte responses to PTOA synovium, a major
limitation is our use of healthy chondrocytes, as OA chondrocytes may respond
differently. Future work may address this by establishing a co-culture model for OA
chondrocytes using cells from the same rat PTOA model.
Given that synovium exerts a significant biological effect on chondrocytes, we postulate
that synovium may therefore be a useful target in the management of cartilage-damaging
diseases such as OA. Regardless of whether chronic synovial inflammation in OA is
harmful or protective, our work demonstrates that the ability of synovium to influence
cartilage outcomes may be a key leverage point in OA management strategies. Therefore,
additional work should target comprehensive assessment of synovial pathophysiology in
OA and deeper investigation into how biological processes in the synovium can be
exploited to achieve a therapeutic benefit. As a proof of concept, the final experiments in
this thesis addressed early PTOA joint responses when synovial macrophages were
altered.
Liposomal drug-treated early PTOA joints showed the histological appearance of
synovitis was significantly affected, confirming a treatment effect. Although cartilage
damage was not apparently affected, treatment was only administered for two weeks,
while most cartilage changes evolve over longer periods in rodent OA models. Moreover,
changes in chondrocytes gene expression likely precede and cause morphologic changes
at the tissue level. In vitro co-cultures showed that synovium from liposome-treated joints
did induce different responses in chondrocytes, suggesting that differences in cartilage
damage and animal pain-related behavior may become apparent at a later stage.
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Synovium-chondrocyte co-cultures and primary macrophage cultures indicate that
STAT1 inhibition may be protective, while STAT6 inhibition may be pro-inflammatory.
As we predicted, synovial macrophage manipulation was able to produce changes in
chondrocyte physiology, and further development and understanding of selectively
altering synovial macrophage behavior could produce therapeutic benefit for OA and
other joint diseases. Although drugs used to treat inflammatory rheumatoid arthritis have
not been shown to be effective for OA, OA-specific anti-inflammatory and anabolic
factors are a current topic of interest. Recent studies have shown that synovial
macrophages drive the production of matrix proteases and their inhibitors by synovial
fibroblasts. Characterization of the synovium as a whole tissue would improve our
understanding of the processes at work. We plan to quantify expression of M1-like, M2like, and pan-macrophage markers in sections from liposome-treated joints for both early
and later stage PTOA.

4.3 Future directions
Ongoing work in the lab will address the limitations of the experiments presented here
and follow new courses of inquiry. We are completing a course of liposome-treated 12W
PTOA joints for analysis by histology and for co-culture of isolated synovium with
chondrocytes to determine longer term effects. We will also use our co-culture model to
examine other treatments for synovium and altering synovial macrophages, such as drugs
affecting other proteins in the polarization dynamic (e.g. STAT3, SOCS, NF-κB). To
continue investigating the protective effect of early PTOA synovium on chondrocytes,
other specific inhibitor assays or wider proteomic studies may be completed on co-culture
medium to determine the signal or signals responsible.
The work completed here is limited by our use of the animal model; these findings
remain to be replicated and expanded upon by studies using female animals, other
methods of OA induction, or human tissue samples. While human tissues are more
directly translatable in physiology and patient diversity, animal studies are still needed to
sufficiently replicate the interaction of local and systemic factors, as well as
biomechanical signalling, which is especially relevant to processes in joint
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homeostasis.Finally, the relative proportions of macrophage subpopulations remain to be
determined, by flow cytometry of isolated synoviocytes or microscopic in situ
quantification. This information would help to interpret our findings and inform future
research questions about synovitis.
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Appendix A: Animal Use Protocol Approval.
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osteoarthritis.
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html
2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including permits and
scientific/departmental peer approvals, are complete and accurate;
c) any divergence from this AUP will not be undertaken until the related
Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full AUP Renewals will be submitted and attended to within timeframes outlined by the
ACC. http://uwo.ca/research/services/animalethics/animal_use_protocols.htm
l
3) As per MAPP 7.10 all individuals listed within this AUP as having any hands-on
animal contact will
a) be made familiar with and have direct access to this AUP;
b) complete all required CCAC mandatory training ( training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of animals.
4) As per MAPP 7.15,
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a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS Veterinarians
and ACC Leaders;
c) UCAC policies and related ACC procedures will be followed, including but
not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visit
5) As per institutional OH&S policies, all individuals listed within this AUP who will
be using or potentially exposed to hazardous materials will have completed in
advance the appropriate institutional OH&S training, facility-level training, and
reviewed related (M)SDS
Sheets, http://www.uwo.ca/hr/learning/required/index.html
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care

The University of Western Ontario
Animal Care Committee / University Council on Animal Care
London, Ontario Canada N6A 5C1
519-661-2111 x 88792 Fax 519-661-2028
auspc@uwo.ca
http://www.uwo.ca/research/services/animalethics/index.html
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Appendix B
Appendix B: Animal Research: Reporting In Vivo Experiments (ARRIVE)
Guidelines Checklist
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